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ABSTRACT 
 
There are currently no published scoring instruments with prior empirical evidence to support the 
validity and reliability of the accuracy of the drug withdrawal scores generated in infants greater 
than 28 days of life with a diagnosis of Neonatal Abstinence Syndrome (NAS). This study was 
done to identify the signs of withdrawal in infants greater than 28 days of life with NAS and 
determine if further adaptation of the modified-FNAST was necessary to accurately measure the 
severity of drug withdrawal in this sub population of infants. This aim could not analyzed due to 
limitations of the data.  
The study was also done to describe the relationship between the medications used to treat the 
infant NAS and the longitudinal trajectory of the Finnegan scores. The results of the study 
revealed that the total modified-FNAST scores ranged from 0-21 on day 1 of life with a mean of 
8.68 and a SD (4.127), and then gradually decreased with less variability over the length of the 
hospitalization until discharge. Four medications were used to treat the infants for NAS. The 
medications used to treat the infants for NAS included morphine (99%), phenobarbital (66.2%), 
clonidine (25.1%), and buprenorphine (1.9%). The minimum to maximum dosage and minimum 
to maximum duration of inpatient treatment days for each of the medications were explored and 
revealed, morphine (dosage range, 0.33-2.170 mg/kg/day and duration of 14-81 days), 
buprenorphine (dosage range 7.00-61.30 mcg/kg/day and duration of 4.00-30.00 days), clonidine 
(dosage range 3.97-28.93 mcg/kg/day and duration of 16.00-87.00 days), and phenobarbital 
(dosage range 3.00-16.00 mg/kg/day and duration of 2.00-84.00 days). Most of the infants 
received morphine alone or in combination with phenobarbital or clonidine consistent with the 
x 
 
established evidence-based NAS weaning protocol. The Mixed Effects Model Analysis revealed 
that there was an overall decrease in the total Finnegan scores over time (p < 0.0001). The mean 
total Finnegan scores showed a statistically significant difference in the groups treated with and 
without clonidine (p = 0.0031). The group treated with clonidine had higher mean total Finnegan 
scores. The infants treated with phenobarbital did not show a significant association with the 
total Finnegan scores (p = 0.6852). In addition, all other control variables failed to show 
significant associations with the repeated measures of total Finnegan scores including: gender (p 
= 0.6257), infant birth weight (p = 0.9375), gestational age (p = 0.8444) and the estimated 
number of cigarettes smoked by the mother during the pregnancy (p = 0.7300).  The interaction 
between the infants treated with clonidine and phenobarbital were not statistical significant 
either. (p = 0.6412). 
Key Words: Neonatal Abstinence Syndrome, opioid, modified-FNAST, reliable, valid, factor 
analysis 
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CHAPTER ONE: 
BACKGROUND 
 
 
Opioid Dependence during Pregnancy/Neonatal Abstinence Syndrome 
 
Opioid dependence during pregnancy poses a serious health risk for the mother and her 
unborn child and places a significant social and economic burden on the United States. 
According to a recent national study, illicit drug use is estimated to be 14.6 % of teenage 
pregnant woman (15-17 years of age), 8.6% in pregnant women 18-25 years of age, and 3.2% 
among pregnant women 26-44 years of age (SAMHSA, 2014). These statistics cause more 
concern given that 55 to 94 % of infants born to drug dependent pregnant women will experience 
some form of withdrawal post-delivery following the abrupt cessation of the continuous supply 
of opioids that they have been exposed to over the duration of the pregnancy (Hudak & Tan, 
2012). The increase in illicit drug use among pregnant women has led to a national epidemic of 
infants born with Neonatal Abstinence Syndrome (NAS). Neonatal abstinence syndrome (NAS) 
is the diagnosis used to describe the typical pattern of drug withdrawal seen in infants born to 
opioid-dependent mothers (Hudak & Tan, 2012; Kocherlakota, 2014). The incidence of NAS 
nationally has increased from 3.4 to 5.8 per 1000 infants born in the United States (Patrick, 
Davis, Lehman, & Cooper, 2015). This represents almost a five-fold increase from 2000 (Patrick 
et al., 2015). Recent local statistics released from the Florida Department of Health (FDOH) 
suggest an even more alarming 10-fold rate of rise in the number of infants discharged with the 
diagnosis of NAS between 1995 and 2014 (FDOH, 2014). Due to the risks associated with acute 
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drug withdrawal, which may include seizures, many infants with NAS require hospitalization 
within the Neonatal Intensive Care Unit (NICU) (Patrick et al., 2015). The average hospital 
length of stay for infants requiring treatment for NAS was estimated to be 25 days (Backes, et 
al., 2012) and more recently, 23 days (Patrick et al., 2015), but there is variability based on the 
pharmacological management and weaning practices of the institution (Zimmermann-Baer, 
Notzli, Rentsch, & Bucher, 2010). Medicaid was reported as the primary payer for the majority 
of costs associated with the care of this population of infants (estimated at approximately 82%) 
(Patrick et al., 2015; Winkelman, Villapiano, Kozhimannil, Davis, & Patrick, 2018). Total 
Medicaid covered costs increased from $65.4 million to $462 million in 2014 for NAS births, 
after adjusting for inflation (Winkelman, et al., 2018).  
The Finnegan Abstinence Scale   
The Finnegan scale was first developed over 40 years ago to quantify the severity of drug 
withdrawal in newborn infants with NAS (Finnegan, Connaughton, Kron, & Emich, 1975). 
Thirty-seven term and near term infants born to drug dependent mothers in Philadelphia were 
assessed using the Finnegan scale (Finnegan et al., 1975). The original Finnegan scale included 
20 specific symptoms common to infants experiencing acute drug withdrawal (Finnegan et al., 
1975). Evidence to support the face, content, and construct validity of the instrument was 
established based on the opinion of a panel of national experts. Psychometric testing (using test-
retest) was also done to provide evidence to support the reliability of the instrument (Finnegan et 
al., 1975). Finnegan scores were obtained on all the infants every hour for the first 24 hours, then 
every 2 hours for the next 24 hours, and then every 4 hours until discharge. The nurses who 
participated in the study were trained to use the instrument and had achieved 90% reliability to 
assess affected infants using scoring instrument (Finnegan et al., 1975). Infants experiencing 
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drug withdrawal with score ranges up to 7 were provided with non-pharmacological measures 
and routine neonatal care (Finnegan et al., 1975). Infants with more severe drug withdrawal, with 
score values of 8 or greater were determined to be pathological, requiring treatment with 
phenobarbital or paregoric (Finnegan et al., 1975). Finnegan et al. (1975) suggested that the 
instrument was superior over subjective clinical assessment of withdrawal, which they described 
as the standard of care at that time. The investigators also reported that there was a reduction in 
the length of required treatment among the infants scored with the Finnegan scale (Finnegan et 
al., 1975). However, on balance, the instrument is lengthy and scoring is complicated by 7 items 
that list more than one value (including 4 that require discernment between excessive/continuous 
crying, hyperactive/markedly hyperactive Moro reflex, and mild/moderate to severe tremors) 
(Finnegan et al., 1975). The individual item scores range from 1 to 5, and total scores for the 
original version ranged from 0 to 46 (Finnegan et al., 1975).   
The Modified Finnegan Abstinence Scoring System 
The Finnegan scoring system was later modified to reduce and eliminate items that were 
found to be redundant or obsolete (Finnegan et al., 1975; Finnegan & Kaltenbach, 1992). 
Modification of the Finnegan Neonatal Abstinence Scoring Tool (FNAST) streamlined the 
clinical efficiency without compromising the validity of inferences about the higher order 
constructs in a population of infants experiencing acute drug withdrawal (Finnegan, 1990; 
Finnegan et al., 1975; Finnegan & Kaltenbach, 1992). Excoriation of the nose, knees, and toes 
(one point each) were reduced to “skin excoriation” (for one point only) after the “Back to 
Sleep” campaign reduced the incidence of infants presenting with the prior pattern of skin 
excoriation (Maguire, Cline, Parnell, & Tai, 2013; Finnegan, 1990; Finnegan & Kaltenbach, 
1992). The modified-FNAST scoring system is considered the gold standard and continues to be 
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the most widely used measurement instrument to assess the severity of drug withdrawal in 
neonates born to drug dependent mothers in the United States (Hudak & Tan, 2012). The 21-item 
modified-FNAST assigns a numeric rating for observed infant withdrawal signs based on the 
level of severity in each of the four main physiologic categories (autonomic, gastro-intestinal, 
respiratory, and central nervous systems) (Finnegan, 1990; Finnegan & Kaltenbach, 1992). The 
range of possible scores that can be obtained using the modified-FNAST are a minimum 0, to a 
maximum of 37 (Finnegan, 1990; Finnegan & Kaltenbach, 1992). Additional psychometric 
testing of the modified-FNAST has been done since its original publication, which includes a 
factor analysis which was performed in infants with NAS who were less than or equal to 28 days 
of life (Maguire, Cline, Parnell, & Tai, 2013), and the instrument was tested in like (Finnegan et 
al., 1975) and divergent populations (Sarkar & Donn, 2006; Zimmermann-Baer, Notzli, Rentsch, 
& Bucher, 2010). This provides further evidence of the validity of inferences about the higher 
order constructs of the modified-FNAST in a population of infants less than or equal to 28 days 
of life with NAS (Shadish, Cook, & Campbell, 2002). Jones et al. (2016) demonstrated poor 
internal consistency of the instrument with Cronbach’s alphas failing to exceed 0.62 at first 
administration, peak NAS score, and NAS treatment initiation. Finally, Gomez-Pomar et al. 
(2017) noted minimal influences of extraneous factors (daily census, time of day, day of the 
week) on observed scores further supporting the clinical utility of the instrument in the 
assessment and management of infants with NAS. 
Other Published Neonatal Abstinence Scoring Instruments 
In addition to the modified-FNAST, multiple other scoring instruments have been 
developed to measure the severity of drug withdrawal infants born to drug dependent mothers 
(Orlando, 2014). Six of the instruments provide a score level indicating when the infant has 
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reached a pathologic range requiring pharmacological management (Finnegan et al., 1975; 
Green, & Suffet, 1981; Lester, Tronick, & Brazelton, 2004; Lipitz, & Blatman, 1974; Jones, 
Kaltenbach, Hei, et al., 2010; Zahorodny, Rom, Whitney, et al., 1998). Four of the instruments 
were developed to rapidly assess drug withdrawal in infants (Chasnoff, & Burns, 1984; Jones, 
Harrow, O’Grady, Crocetti, Jansson, & Kaltenbach, 2010; Maguire, Cline, Parnell, & Tai, 2013; 
O’Brian, Hunt, & Jeffery, 2004). The advantages and disadvantages of the abstinence scoring 
instruments vary, and none of them have been tested in older age infants (greater than 28 days of 
life). According to Orlando (2014), existing instruments for assessment of drug withdrawal in 
infants (0-28 days of life) include the following:  
(1) Neonatal Drug Withdrawal Scoring System (Lipitz, & Blatman, 1974; Lipsitz, 1975) 
(2) Neonatal Narcotic Withdrawal Index (Green, & Suffet, 1981) 
(3) The Moro Scale Score (Chasnoff, & Burns, 1984) 
(4) Neonatal Withdrawal Inventory (Zahorodny, Rom, Whitney, et al., 1998).  
(5) Measurement of Movement (O’Brian, Hunt, & Jeffery, 2004) 
(6) Neonatal Network Neurobehavioral Scale Part II: Stress/Abstinence Scale (Lester, Tronick, 
& Brazelton, 2004) 
(7) The Mother Opioid Treatment Experimental Research NAS Scale (MOTHER NAS Scale) 
(Jones, Kaltenbach, Hei, et al., 2010) 
(8) Three-Sign Screening Index (Jones, Harrow, O’Grady, Crocetti, Jansson, & Kaltenbach, 
2010) 
(9) Finnegan Neonatal Abstinence Scale-Short Form (Maguire, Cline, Parnell, & Tai, 2013) 
The Neonatal Drug Withdrawal Scoring System has a total of 11 items, 7 of the items 
(skin abrasions, respirations, tremors, irritability, reflexes, muscle tone, and stools,) are scored on 
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a scale of 0-3. The remaining 4 items (vomiting, sneezing, repetitive yawning, and fever) are 
assigned a score of 1 if present and 0 when absent. A score of 10 or greater, according to the 
authors, indicates the need for pharmacological treatment of the infant (Lipitz, & Blatman, 
1974). 
The Neonatal Narcotic Withdrawal Index was developed to simplify the assessment of 
narcotic withdrawal severity and was published complete with item definitions to promote 
interrater reliability (Green, & Suffet, 1981). The instrument includes 7 items: crying, tremors, 
muscle tone, respiratory rate, axillary temperature, vomiting, and other signs. Items are assigned 
a point value of 0-2, higher scores indicate greater severity of withdrawal symptoms (Green, & 
Suffet, 1981). The other signs category is scored for the presence of any of the following: 
sneezing, diarrhea, sweat, skin abrasions, generalized seizures, localized seizures, poor suck, 
salivation, yawning, stuffy nose, hiccoughs, and weight loss observed in the preceding 24 hours 
(Green, & Suffet, 1981). Infants are assigned a maximum item score of 2 in the other signs 
category when they are noted to have 5 or more of the operationally defined signs (Green, & 
Suffet, 1981). Pharmacological management is indicated by a cumulative score of 5 or greater on 
at least 2 evaluations within a 24-hour period (Green, & Suffet, 1981). According to the authors, 
a score of 3 or less by 24 to 36 hours suggests adequate treatment and weaning is recommended 
when scores drop to 3 or less for 48 to 72 hours (Green, & Suffet, 1981). 
The Moro Scale Score was designed to provide a method of following the process of drug 
withdrawal in term infants over the first year of life, and to identify infants at risk for 
developmental delay (Chasnoff, & Burns, 1984). The instrument provides a means for assessing 
central nervous system (CNS) irritability over time, but is not recommended to be used as a basis 
to make pharmacological treatment decisions in the acute phase of drug withdrawal. The Moro 
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reflex which is present at birth is expected to gradually disappear by 3-4 months in healthy 
newborns. However, this reflex persists in opioid infants (Finnegan, et al., 1975). The intensity 
of all six movements that comprise the Moro response are examined using this instrument 
(Chasnoff, & Burns, 1984). The six movements evaluated include abduction at the shoulder, 
adduction at the shoulder, extension at the elbow, tremors, and the threshold that triggered a 
Moro response (Chasnoff, & Burns, 1984). Each of the items are scored 0-3, total scores range 
between 0-20 (Chasnoff, & Burns, 1984). The authors provide no definitions for the individual 
items, but the procedure for eliciting the Moro response is described (Chasnoff, & Burns, 1984). 
Neonatal Withdrawal Inventory (NWI) is a 7 item rapid clinical assessment instrument 
designed to assess CNS, gastrointestinal, autonomic, and behavioral signs of withdrawal in drug 
exposed newborns (Zahorodny, et al., 1998). The signs include hyperactive Moro reflex, 
hypertonicity, tremor, sweating and mottling, recurrent yawning and sneezing, regurgitation and 
diarrhea, and behavioral distress (Zahorodny, et al., 1998). The NWI items are scored from 1 to 4 
with higher values assigned to items with greater clinical importance (Zahorodny, et al., 1998). 
The possible score range for the NWI is from 0 to19, with a score of 8 or greater considered to 
be pathological requiring treatment (Zahorodny, et al., 1998). Interrater reliability for the NWI 
has been shown to be high mean reliability coefficient documented at 0.93 between 4 trained 
observes who completed 30 assessments (Zahorodny, et al., 1998).  
Measurement of movement using an actigraph was studied by O’Brian, Hunt, and Jeffery 
(2004) to assess the degree of hyperactivity as a measure of severity of drug withdrawal in 
infants with NAS. The actigraph device was strapped to the infant’s wrist or leg to detect and 
record movements (O’Brian, Hunt, & Jeffery, 2004). Measurements of hyperactivity obtained 
from the actigraph device are continuously compared with serial assessment performed by a 
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trained observer (O’Brian, Hunt, & Jeffery, 2004). Computer software developed for use with 
the device are required to analyze the activity log (O’Brian, Hunt, & Jeffery, 2004). The 
investigators compared the movement of NAS infants experiencing acute drug withdrawal to 
healthy term infants (O’Brian, Hunt, & Jeffery, 2004). The results of the actigraph recordings 
were compared with scores obtained from traditional scoring systems (O’Brian, Hunt, & Jeffery, 
2004). The actigraph activity score calculated from analysis of motion identified those infants 
who required treatment on the basis of their traditional assessment score with high sensitivity and 
specificity (O’Brian, Hunt, & Jeffery, 2004). The costs associated with the purchase of an 
actigraph and required software for analysis were not reported. At this stage of testing, actigraph 
may have potential for screening infants for NAS however, further research is needed before the 
device can be used for clinical monitoring of infants with NAS (Orlando, 2014).  
The NICU Network Neurobehavioral Scale (NNNS) is a comprehensive 115 item scale 
designed to examine maternal lifestyle and newborn outcomes following drug exposure 
prenatally (Lester, Tronick, & Brazelton, 2004). The stress/abstinence sub scale is a part of this 
comprehensive instrument which was developed for use in a multicenter research study (Lester, 
Tronick, & Brazelton, 2004). The stress/abstinence scale is divided into 7 sections including 
physiologic, autonomic, CNS, visual, skeletal, gastrointestinal, and state (Lester, Tronick, & 
Brazelton, 2004). There are no numeric scores assigned (Lester, Tronick, & Brazelton, 2004). 
Infants are given a yes if the item is present and no if it is absent (Lester, Tronick, & Brazelton, 
2004). The authors suggest the instrument is appropriate for premature infants 30 weeks 
gestational age or greater and less than 48 weeks post corrected age (Lester, Tronick, & 
Brazelton, 2004). The NNNS Stress/Abstinence Scale is recommended to be used screen at risk 
infants for abnormal behaviors (Lester, Tronick, & Brazelton, 2004). Drug exposed infants who 
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screen positive may require additional evaluation with a comprehensive neonatal abstinence 
scoring system for the purpose of initiating pharmacological treatment and ongoing monitoring 
of the infant (Lester, Tronick, & Brazelton, 2004). 
The Maternal Opioid Treatment: Human Experimental Research NAS Scale (MOTHER 
NAS Scale) was developed for use in a comprehensive treatment program for drug-dependent 
mothers and infants (Jansson, Valez, & Harrow, 2009). The instrument was first described as a 
modified version of the Finnegan Neonatal Abstinence Scoring System however, later 
publications referred to the instrument as the Maternal Opioid Treatment: Human Experimental 
Research NAS Scale (Jansson, Valez, & Harrow, 2009; Jones, Kaltenbach, Hei, et al., 2010). 
The instrument has 28 items, nineteen of the 28 items contribute to the total score and are used to 
determine when pharmacological treatment is indicated. The remaining 9 items are assessed as 
present or not but do not contribute to the total score (these items were assessed as part of the 
study protocol but were not used to determine the need for treatment) (Jones, Kaltenbach, Hei, et 
al., 2010). The scored items were given point values ranging from 1 to 3, except seizures which 
was given a point value of 8 (Jones, Kaltenbach, Hei, et al., 2010). The total score range is from 
0 to 42 (Jones, Kaltenbach, Hei, et al., 2010). 
Three-Sign Screening Index was developed as a rapid assessment screening instrument 
(Jones, et al., 2010). Three items from the modified Finnegan neonatal abstinence scoring 
instrument (the Maternal Opioid Treatment: Human Experimental Research NAS) were 
determined by the investigators to discriminate between opioid exposed and non-exposed infants 
(Jones et al., 2010). Hyperactive Moro reflex, mild tremors when undisturbed, and increased 
muscle tone were observed in the drug exposed group of infants and not in the non-exposed 
infants (Jones et al., 2010). The investigators proposed the 3-item index as a cost-effective 
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method of screening infants for opioid exposure when the infant has not been identified as high 
risk by maternal drug history (Jones et al., 2010). The instrument was not designed for use as 
assessment, monitoring, or weaning instrument. The Three-Sign Screening Index was meant to 
be used for screening potential at risk infants who need further evaluation using a more 
comprehensive assessment instrument (Jones et al., 2010). 
The Finnegan Neonatal Abstinence Scale-Short Form was developed after factor analysis 
of more than 30,000 neonatal assessment scores to determine if the 21 item modified Finnegan 
scoring instrument could be reduced to the least number of items and still retain the reliability 
and validity of the instrument (Maguire, Cline, Parnell, & Tai, 2013). Factor analysis revealed a 
2 factor solution which was labeled as early or mild signs, and moderate or progressing signs. 
The 7-item Finnegan Neonatal Abstinence Scale-Short Form included 3 mild signs (crying, sleep 
disturbances, and increased muscle tone), and 4 moderate or progressive signs (tremors, 
respiratory rate, sweating, and excessive sucking) (Maguire, et al., 2013). The instrument is 
scored using the same point values as the original instrument. Scores of 8 or greater are 
considered pathological and require treatment. The reduced number of items on the instrument 
may have significant advantages over existing instruments related to ease of use, and reduction 
in the necessary training time required to achieve inter-observer reliability (Maguire, et al., 
2013). The short form may have utility for monitoring infants post discharge in the home or 
when followed up at the Pediatrician’s office (Maguire, et al., 2013). The investigators caution 
that the short form may not be adequate to assess infants with rapidly escalating signs and 
symptoms of acute drug withdrawal, and therefore recommend that these infants be assessed 
with a more comprehensive instrument such as the 21-item modified-FNAST (Maguire, et al., 
2013). The investigators also suggest that further testing is required before the Finnegan 
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Neonatal Abstinence Scale-Short Form can be recommended for widespread use (Maguire, et al., 
2013). 
More recently, two additional scoring instruments have emerged, the simplified Finnegan 
Neonatal Abstinence Scoring System (sFNAS) (Pomar, et al., 2017), and the Eat, Sleep, Console 
(ESC) (Grossman, Lipshaw, Osborn, & Berkwitt, 2018). Analysis of 40 294 observations using 
multiple statistical analyses (generalized estimating equations, linear regression, and correlation),  
and cross validation to simplify the Finnegan Neonatal Scoring System to 10 items. The sFNAS 
includes cry, tremors, increased muscle tone, sleep, nasal stuffiness, respiratory rate, excessive 
sucking, poor feeding, feeding intolerance, and stool assessments. Scores range from 0 - 23 with 
higher scores indicating more severe drug withdrawal. The authors recommend treating infants 
when scores are greater than 6 and 10 respectively (compared to two consecutive scores >8 or 
one score of 12, the cutoffs established for pharmacological management in the Finnegan 
Neonatal Scoring System). The scoring instrument demonstrated a high correlation (r = .914) 
with the Finnegan Neonatal Scoring System (Pomar, et al., 2017). Further empirical testing is 
needed to determine if the instrument has clinical utility, and establish the validity and reliability 
of the instrument (Pomar, et al., 2017). 
The ESC is a neonatal drug abstinence scale developed to assess and treat only infants 
with NAS who are determined to be unable to perform essential functions characteristic of a 
healthy newborn (eat a minimum of at least 1 ounce per feeding or breastfeed, sleep > to 1 hour, 
and be consoled within 10 minutes from a cry state) (Grossman, et al., 2018). The instrument 
was developed to assess the functional status of the infant and reduce the potential for over 
treatment of infant drug withdrawal based solely on the total infant withdrawal score. Infants 
with NAS who are eating, sleeping, and easily consoled are assessed to be stable. Infants with 
12 
 
NAS who are unable to maintain their functional status according to the established criteria are 
provided additional support with nonpharmacological treatment. If nonpharmacological 
treatment fail the infant was treated with an oral dose of morphine (0.05 mg/kg/dose) and then 
re-evaluated (Grossman, et al., 2018). A retrospective chart review was done to compare the 
treatment decisions of 50 infants with NAS who were clinically assessed using the ESC 
approach. The investigators reported that using the ESC criteria resulted in only 6 (12%) of the 
infants requiring treatment with morphine compared to 31 infants (62%) predicted to require 
treatment using the Finnegan Neonatal Abstinence Scoring System (which was statistically 
significant, p < .001). In addition, there were no adverse events or readmissions during the study 
period (Grossman, et al., 2018). 
The modified F-NAST was developed to assess the severity of drug withdrawal in full 
term infants less than or equal to 28 days of life, however, the instrument is being used clinically 
on premature and infants greater than 28 days of life. The modified-FNAST has never been 
empirically tested for evidence of validity and reliability of the scores generated in NAS infants 
greater than 28 days or premature infants. Sleep wake cycles, one of the items assessed on the 
modified-FNAST, are known to change rapidly between the neonatal period and early infancy 
(Tarullo, Balsam, & Fifer, 2011). Newborn infants sleep at least 16-18 hours per day between 
feedings (Tarullo et al., 2011). As infants mature, the total sleeping time gradually decreases 
(Tarullo et al., 2011) and they begin to sleep longer at night (Hockenberry & Wilson, 2009), 
which has the potential to impact their modified-FNAST scores. Despite the lack of empirical 
evidence, the modified-FNAST is frequently used inappropriately in this sub-population of NAS 
infants because there are no instruments with empirical evidence to support the measurement of 
acute drug withdrawal for this group of infants. This poses a potential risk for these infants 
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because decisions regarding pharmacological management and discharge are frequently made 
based on the assessed modified-FNAST scores. 
An exploratory factor analysis will be done to assess the degree to which the validity and 
reliability of the scores generated from the modified-FNAST can be extended to infants greater 
than 28 days of life. A series of factor analyses of the averaged modified-FNAST scores of NAS 
infants less than and greater than 28 days of life who are admitted to a 97 bed NICU between 
January 1, 2010-May 18, 2018 will be performed. The average modified-FNAST scores for the 
infants with NAS on day 1, 3, 7, and then weekly, and on the day of discharge from the NICU 
will be factor analyzed to determine the underlying dimensions to assess the similarities and 
differences over time. A factor analysis is a statistical approach used to establish empirical 
evidence of construct validity for a measurement instrument with sub scales. The approach is 
used to provide justification for the inclusion of the dimensions and their individual contribution 
to the accuracy of measuring the phenomena of interest in a specific population of patients 
(Waltz, Strictland, & Lenz, 2010).  Given that the Finnegan includes all the common signs of 
drug withdrawal, the instrument should provide a good basis for performing a factor analysis. 
The factor analyses will be used to identify the signs that most accurately describe drug 
withdrawal in this population which may be different from infants less than 28 days of life. The 
identified signs of acute withdrawal can then be compared with what has been reported in the 
literature.  
Statement of the Problem 
There are currently no published scoring instruments with prior empirical evidence to 
support the validity and reliability of the accuracy of the drug withdrawal scores generated in 
infants greater than 28 days of life. This study was needed to identify the signs of withdrawal in 
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infants greater than 28 days of life with NAS, and determine if further adaptation of the 
modified-FNAST was needed to accurately measure the severity of drug withdrawal in this sub 
population of infants. 
Statement of Significance and Innovation 
The incidence of NAS has more than tripled over the past decade with approximately 3.4 
out of every 1000 infants born in the United States diagnosed with this serious condition (Patrick 
et al., 2012). Most infants with NAS require hospitalization (NICU) for at least 5-7 days to 
monitor the infant for potential life threatening symptoms of acute drug withdrawal (Patrick et 
al., 2012). According to Patrick et al. (2012), Medicaid is the most frequent insurance provider 
for this population of infants, and the average cost for an infant diagnosed with NAS at discharge 
is $53 400 based on their 2009 data. The length of hospital stay for infants with NAS has been 
shown to be decreased as a result of the change in pharmacological management (treatment with 
buprenorphine as compared to methadone) (Noormohammadi et al., 2016), the implementation 
evidence-based practice weaning guidelines (Holmes et al., 2016; Murphy-Oikonen, 
Montlelpare, Bertoldo, Southon, & Persichino, 2012), rooming-in (Holmes et al., 2016),  and the 
emergence of early discharge home weaning programs for eligible mother-infant dyads. Despite 
these advancements, there is still a sub population of NAS infants greater than 28 days of life 
who are potentially at greater risk because treatment decisions (weaning of opioid replacement 
and discharge) are based on modified-FNAST scores when there is no empirical evidence to 
support the scores in this group. The study is innovative because the design provides a cost 
effective and efficient method to discern the goodness of fit of the modified-FNAST in this 
previously unstudied population of high-risk NAS infants from an existing de-identified data 
source. 
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Purpose 
The purpose of this study was to examine which items included in the modified-FNAST 
are observed in infants with NAS less than and greater than 28 days of life, explore how they are 
correlated with one another, and determine which items are most predictive of severity of drug 
withdrawal in infants greater than 28 days. The study explored the interrelationships among a set 
of variables in infants with NAS less than and greater than 28 days of age to determine the 
underlying structure in order to determine if there is a need for further customization of the 
modified-FNAST for use in infants greater than 28 days of life. In addition, the study described 
the relationship between the medications used to treat the infant NAS and the longitudinal 
trajectory of the Finnegan scores.  
Hypothesis 
The structure of the modified-FNAST (as determined by an exploratory factor analysis) 
in a sample of infants greater than 28 days of life diagnosed with NAS who are experiencing 
acute drug withdrawal will be different than prior research done in infants 0-28 days of life (see 
Figure 1. Logic Model, & Figure 2. Deconstruction of Logic Model below). 
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Figure 1. Logic Model 
 
Figure 2. Deconstruction of the Logic Model 
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Study Aims  
Aim #1. Determine which of the 21 items in the modified-FNAST are most predictive of 
the need for pharmacological treatment in infants greater than 28 days of life diagnosed with 
NAS. 
Aim #2. Explore the interrelationships among the 21 items of the modified-FNAST to 
determine the underlying structure in infants less than 28 days of life diagnosed with NAS 
experiencing acute drug withdrawal. 
Aim #3. Explore the interrelationships among the 21 items of the modified-FNAST to 
determine the underlying structure in infants greater than 28 days of life diagnosed with NAS 
experiencing acute drug withdrawal.  
Aim #4. Compare the underlying structures of the interrelationships of the items of the 
modified-FNAST as determined by a series of exploratory factor analyses (EFA) in infants less 
than and greater than 28 days of life diagnosed with NAS experiencing acute drug withdrawal.  
AIM #5. Describe the relationship between the medications used to treat the infants for 
NAS and the longitudinal trajectory of the Finnegan scores. 
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CHAPTER TWO: 
LITERATURE REVIEW 
 
 
The chapter includes an overview of the theoretical framework for this study, and a 
review of the literature relevant to the published screening and measurement instruments and the 
care and treatment of infants with NAS that informed the development of this study. The 
electronic databases of Cumulated Index of Nursing and Allied Health Literature Plus (CINAHL 
Plus) and Medical Literature Analysis and Retrieval System Online (MEDLINE) (via Pub Med) 
were searched to retrieve current relevant articles for inclusion in this review of the literature. 
The terms neonatal abstinence syndrome, and care and treatment, were used for the literature 
search. The search was limited to research articles published from 2010 to 2018, English 
language only, with a focus on the care and treatment of infants with NAS (nonpharmacological 
and pharmacological) and prior psychometric testing of the modified-FNAST. The article search 
retrieved a total of 124 potential abstracts from CINAHL Plus and a total of 274 from MEDLINE 
(via Pubmed). Twelve studies were added through other sources (n = 410).  Duplicate abstracts 
(n = 80) were eliminated and 330 records were retained. Another 250 articles were removed after 
reviewing the abstracts (including non-research studies, or studies that were not relevant to the 
focus of this study). Eighty articles were then retained for eligibility. Each of the research articles 
were then read and those that provided relevant evidence related to the care and treatment of 
infants with NAS (nonpharmacological and pharmacological) and prior psychometric testing of 
the modified-FNAST were retained. A total of 34 research studies were included in the review of 
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the literature (see Figure 3. Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) Flow Diagram of Search Strategy (Care and Treatment of the Infant with 
NAS).  
 
Figure 3. PRISMA Flow Diagram of the Search Strategy (Care and Treatment of the Infant with 
NAS) 
The specific studies that provide empirical referents and related research on the care and 
treatment of NAS and prior psychometric testing of the modified-FNAST are detailed in Table 1. 
Synthesis Table (see Appendix A). The table provides an overview of rigor and quality of the 
evidence related to this concept. The supplemental table provides the author(s), year, title, 
purpose, target population, inclusion and exclusion criteria, sample size, response rate, design, 
statistical method, variables, instruments, interventions, selected findings, clinical significance, 
and limitations of the study.   
The review of the literature related to the care and treatment of infants with NAS 
identified several important substanitive themes that provide further clarification of the term 
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NAS. The themes include definitions of NAS, screening and measurement instruments for 
infants at risk, pharmacological, and non-pharmacological interventions for infants with NAS. 
Theoretical Framework: The Biological (Disease) Model of Addiction 
 
According to the National Institute on Drug Abuse (NIDA) (2016), addiction is defined 
as, “a chronic, relapsing brain disease that is characterized by compulsive drug seeking and use, 
despite harmful consequences. It is considered a brain disease because drugs change the brain; 
they change its structure and how it works. These brain changes can be long lasting and can lead 
to many harmful, often self-destructive, behaviors” (NIDA, 2016, p, 1). The biological (disease) 
model of addiction will be used for the purpose of this proposed research study as the theoretical 
framework. The biological (disease) model Leshner (1997) is the most widely accepted theory on 
addiction and provides a basis to understand the complexity of addiction and recovery in the 
context of the opioid dependent mother and her infant with NAS (Leshner, 1997; NIDA, 2016).  
According to this model opioid addiction begins with the initial experimentation with the 
drug. It is thought that the most susceptible females may experience the greatest pleasurable 
effects from the drug (Leshner, 1997). With continued use of the drug the girl or woman 
becomes physically dependent to the drug (NIDA, 2016). Physical dependence is defined as the 
need to consume the drug in order to avoid experiencing withdrawal symptoms (Leshner, 1997; 
NIDA, 2016). Addiction is considered a brain disease because with continued use there is down 
regulation of the dopaminergic receptors in the brain such that the women requires higher 
amounts of the drug to experience the same euphoric effects from the drug that she once 
experienced when she first began experimenting with the drug (Leshner, 1997; NIDA, 2016). In 
addition, the effects of the drug do not last as long. As a result, drug dependent women 
frequently keep increasing the amount of the drug chasing a high they may never achieve again 
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(Leshner, 1997; NIDA, 2016). The phenomena of dose escalation that is seen in addicts often 
leads to overdose and death especially for addicts who do not enter drug treatment (NIDA, 
2016). 
As the drug levels fall, the drug-dependent women experiences intense drug craving and 
increasing signs of acute drug withdrawal which leads to drug seeking behaviors despite 
increasing negative consequences (loss of job, family, home) (NIDA, 2016). Over time the drug 
dependent women without treatment becomes completely consumed with securing drugs to 
reduce drug craving and signs of acute drug withdrawal (NIDA, 2016). Consumed by the power 
of drug addiction, the drug dependent woman who is not in treatment may place herself in high 
risk environments, commit crimes in order to secure funding to purchase drugs (prostitution, 
shop lifting), neglect her own physical, mental, and dental health, and neglect or abuse their own 
children (NIDA, 2016). 
Addiction is a chronic disease that is best treated using an evidence-based comprehensive 
treatment program (NIDA, 2016). NIDA (2012) outlines 13 principles to guide effective 
treatment programs. It is recommended that pregnant opioid dependent women receive treatment 
for at least 90 days to 1 year for it to be most effective (Casey, Makin, & Finigan, 2012). The 
women do not need to enter treatment voluntarily to benefit from treatment, therefore, opioid 
dependent women are frequently mandated into drug treatment by the drug courts (Casey, 
Makin, & Finigan, 2012). As part of a comprehensive drug treatment program, pregnant opioid 
dependent women are started on methadone or buprenorphine to prevent drug craving and acute 
drug withdrawal which can be life threating to the fetus (Hudak, & Tan, 2012). Pregnant women 
in drug treatment on opioid replacement therapy have been shown to have improved prenatal 
care, better weight gain, and perinatal outcomes that were superior compared to pregnant women 
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who continue to use illicit drugs (Hudak, & Tan, 2012). Infants who are born to pregnant women 
on opioid replacement therapy are at risk for developing NAS (Hudak, & Tan, 2012). Infants 
with NAS are not psychologically addicted, but they are physically dependent on the drug and 
will experience signs of drug withdrawal. Therefore, they need to be monitored and if they reach 
a pathological state of withdrawal they will be treated with pharmacological management and 
gradually weaned off the drug (Hudak, & Tan, 2012). 
Definitions of NAS 
NAS is not defined in the Merriam-Webster’s Collegiate Dictionary (2014), however, the 
individual terms are defined. The adjective neonatal is defined as, “of, relating to, or affecting 
the newborn and especially the human infant during the first month after birth” (Merriam-
Webster's Collegiate Dictonary, 2014, p. 831). The noun abstinence is defined as, “voluntary 
forbearance especially from indulgence of an appetite or craving or from eating some foods” 
(Merriam-Webster's Collegiate Dictionary, 2014, p. 5). Syndrome is defined as, “a group of 
signs and symptoms that occur together and characterize a particular abnormality or condition” 
(Merriam-Webster's Collegiate Dictionary, 2014, p. 1268). The Taber’s Cyclopedic Medical 
Dictionary (2009) defines NAS as, “any of the adverse consequences in the newborn from 
exposure to addictive or dangerous intoxicants during fetal development” (Taber's Cyclopedic 
Medical Dictionary, 2009, p. 1588). 
Congenital morphinism/congenital neonatal addiction. The first documented case of 
neonatal drug withdrawal in Western culture was reported in 1875 in Germany (Menninger-
Lerchenthal, 1934), followed by reported cases in the United States in 1892 (Happel, 1892). The 
emerging understanding of the clinical presentation of the newborns with drug withdrawal 
termed congenital morphinism (Goodfriend, Shey, & Klein, 1956; Perlstein, 1947; Pettey, 1912).  
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Congenital Neonatal Addiction. Rosenthal, Patrick, and Krug (1964) later termed the 
condition infant addiction or congenital neonatal addiction. Finnegan et al. (1975) described 
NAS as a medical condition observed in infants experiencing opiate withdrawal and developed a 
scoring instrument to measure the severity of withdrawal. The Finnegan scale was originally 
developed to measure the severity of drug withdrawal in infants with NAS born to heroin 
dependent mothers (Finnegan et al., 1975). The Finnegan scoring system was later modified to 
remove items that were later noted to be repetitive or outdated without compromising the validity 
of inferences about the higher order constructs in a population of NAS infants (Finnegan, 1990; 
Finnegan et al., 1975; Finnegan & Kaltenbach, 1992). NAS was later defined as a constellation 
of drug withdrawal symptoms observed in infants born to opioid-dependent mothers following 
the abrupt termination of intrauterine exposure to opiates (Hudak & Tan, 2012).  
The pattern of NAS may include central nervous system, respiratory system, gastrointestinal 
system, and autonomic system related signs (see Table 1) (Finnegan, et al., 1975; Hudak, & Tan, 
2012). 
Table 1. Signs of Withdrawal Characteristic of NAS  
Central Nervous System Respiratory System Gastrointestinal System Autonomic System 
Increased muscle tone Tachypnea Excessive, uncoordinated 
sucking 
Mottling 
Tremors Retractions Poor feeding Sweating 
High-pitched cry  Vomiting Sneezing 
Apnea  Diarrhea Yawning 
Seizures   Nasal congestion 
 
Neonatal Withdrawal Syndrome (NWS).  NWS is a term that was first introduced in 
the healthcare literature to describe the range of neurological and behavioral symptoms observed 
in neonates born to mothers with a history of illicit drug use (Levy & Spino, 1993). Some 
authors suggest the terms NAS and NWS can be used interchangeblely to describe the physical 
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dependence of infants born to drug dependent mothers (Hekman, Grigorescu, Cameron, Miller, 
& Smith, 2013; Kocherlakota, 2014). Although opioids are the most common intrauterine drug 
exposure known to cause NAS, some definitions include multiple illicit drugs as possible causes 
of NAS (Roussos-Ross, Reisfield, Elliot, Dalton, & Gold, 2015). This broader view of the term 
is relevant given the fact that many drug dependent women are poly-drug users. The use or abuse 
of prescription and non-prescription drugs, opioids, and other psychoactive substances such as 
alcohol, benzodiazepines, cocaine, nicotine and selective serotonin reuptake inhibitors (SSRI) by 
pregnant women are therefore included in some broad definitions of NAS (McLemore, Lewis, 
Jones, & Gauda, 2013; Patrick et al., 2012; Roussos-Ross et al., 2015).   
Neonatal Abstinence Syndrome. NAS is a consequence of in utero exposure to drugs 
from their drug-dependent mother. NAS is characterized by a constellation of withdrawal 
behaviors involving central nervous system (CNS) related signs (tremors, increased muscle tone, 
seizures and high-pitched cry), respiratory system related signs (tachypnea, and retractions), 
gastrointestinal system related signs (poor feeding, vomiting, diarrhea, and uncoordinated and 
excessive sucking), and autonomic system related signs (mottling, nasal stuffiness, excessive 
yawning, sneezing, and temperature) (Finnegan et al., 1975; Hudak & Tan, 2012).  
Neonatal Opioid Withdrawal Syndrome (NOWS) is now being used more commonly 
to describe the specific clinical presentation and treatment of acute infant drug withdrawal from 
in utero exposure to opioids (Marcellus, 2018; Sutter, Leeman, & His, 2016). These infants are 
seen as a subpopulation of infants with NAS. Factors that may impact the severity of NOWS 
include the specific opioid of exposure, gestational age of the infant, maternal history of 
polydrug use, tobacco, the infant’s own genetic predisposition for state regulation, rooming-in, 
and breastfeeding (Sutter, et al., 2016). 
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Expectant management for the opioid dependent pregnant women includes opioid 
maintenance therapy with methadone or buprenorphine (Noormohammadi et al., 2016; Women 
& American Society of Addiction, 2012). NAS associated with in utero buprenorphine exposure 
is less severe than exposure to methadone, suggesting that buprenorphine may be a more 
effective treatment option for the newborn provided the mother’s addiction can be safely 
controlled (Hudak & Tan, 2012). Gaalema et al. (2012) described different clinical profiles 
between infants with NAS born to mothers dependent on methadone (undisturbed tremors and 
hyperactive Moro reflex) versus infants exposed to buprenorphine (nasal stuffiness, frequent 
sneezing, and loose stools) based on secondary analysis of data collected from the Maternal 
Opioid Treatment: Human Experimental Research (MOTHER) study. The onset and severity of 
NAS is dependent on the primary substance the infant is withdrawing from, the combination of 
substances the infant was exposed to, and the gestational age of the infant.   
A recent study revealed that premature infants were just as likely to be monitored for 
NAS but had lower modified-FNAST scores and were less likely to receive treatment than full 
term infants (Ruwanpathirana et al., 2015). The investigators questioned whether this was due to 
physiologic immaturity for less severe withdrawal. Cramton and Gruchala (2013) suggest 
premature infants have been shown to experience a milder form of NAS which is thought to be 
related to immaturity of the CNS, lower fat deposits of the drug, and lower amounts of total drug 
exposure. Maguire et al. (2016) caution that the premature infants may have a less robust 
response to drug withdrawal given their level of immaturity, and the current instruments may not 
be sensitive enough to accurately assess the severity of drug withdrawal in this population.  
The short half-life of opiates is responsible for the rapid onset of the symptoms 
characteristic of NAS, which usually are noted within 72 hours after birth in infants born to 
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mothers who are opioid-dependent (Cramton & Gruchala, 2013). Methadone exposed newborns 
present with symptoms 2-6 days after birth, and sedative-hypnotics (benzodiazepines and 
barbiturates) exposed newborns in comparison may not manifest symptoms of NAS until a week 
or more after birth (Cramton & Gruchala, 2013). Gaalema et al. (2012) reported a significant 
difference between infants with NAS exposed to methadone who required treatment at 36 hours 
compared to infants with NAS exposed to buprenorphine who required treatment at 59 hours of 
age.   
Polysubstance abuse (opioids and benzodiazepines in particular) have been shown to 
produce more severe symptoms of NAS when compared to exposure to a single substance 
(Cramton & Gruchala, 2013). The dose of opiate the infant was exposed to in utero does not 
seem to correlate with the severity of NAS (Thajam, Atkinson, Sibley, & Lavender, 2010). 
Wachman et al. (2014) reported that opioid exposed infants with a more severe phenotype of 
NAS (who had an increase in DNA methylation of 3 CpG sites in the OPRM1 promoter region) 
experienced more severe signs of NAS, consistent with gene silencing. 
Screening & Measurement Instruments for Infants at Risk for NAS 
Maternal and Infant Screening for NAS. AAP guidelines (2012) recommend a 
maternal screening instrument be used along with infant urine and meconium testing to identify 
infants with NAS and the specific drug(s) of fetal exposure (Hudak & Tan, 2012). Universal 
maternal screening utilizing interview and drug testing is recommended given that the self-
reported rates of illicit drug use during pregnancy is often under reported when drug history is 
obtained by interview alone (Hudak & Tan, 2012). Murphy-Oikonen, Montelpare, Southon, 
Bertoldo, and Persichino (2010) completed a one year retrospective chart review to analyze 
whether the consistent use of a standardized screening protocol would accurately detect infants at 
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risk for developing NAS. The standardized screening protocol combined the sensitivity of the 
maternal self-report, urine drug screen, and meconium testing in an attempt to better identify 
infants with NAS and ascertain the most accurate method of detecting substance exposure. The 
investigators reported that there were discrepancies between the mother’s self-report and the 
urine and meconium drug screen results (Murphy-Oikonen et al., 2010). The urine drug screen 
provided a faster screen and the results were available to the practitioners within 24 to 72 hours, 
however, the meconium drug screen provided a more accurate reflection of the maternal drug use 
over the pregnancy (Murphy-Oikonen et al., 2010). To achieve the most accurate reflection of 
the maternal drug use over the duration of the pregnancy and identify which infants are at 
greatest risk for NAS, the authors recommended using a combination of all three screening 
approaches due to the specific limitations of each approach when implemented alone (Murphy-
Oikonen et al., 2010).   
Modified-Finnegan Neonatal Abstinence Scoring Tool (Modified-FNAST). The 
Finnegan scale was developed to measure the severity of drug withdrawal in infants with NAS 
(Finnegan et al., 1975). The Finnegan scoring system was later modified to reduce and eliminate 
items that were found to be redundant or obsolete. The instrument was later modified to 
eliminate redundant items without compromising the validity of inferences about the higher 
order constructs in a population of NAS infants (Finnegan, 1990; Finnegan et al., 1975; Finnegan 
& Kaltenbach, 1992). The modified-FNAST scoring system is the most widely used 
measurement instrument to assess the severity of drug withdrawal in neonates born to drug 
dependent mothers in the United States (Hudak & Tan, 2012).  
Inter-rater reliability using the Modified-FNAST. In order to promote consistency and 
accuracy of withdrawal scores among nurses, D'Apolito (2014) suggested that NICU nurses 
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receive additional knowledge and training to become reliable in scoring the modified-FNAST. 
D'Apolito and Finnegan (2010) developed an educational program to establish interrater 
reliability among staff when scoring the modified-FNAST. The program includes the standard 
definitions for each item on the modified-FNAST, a demonstration of each, and the nurses are 
required to achieve at least 90% agreement scoring an infant using the modified-FNAST 
(D'Apolito, & Finnegan, 2010). Accuracy of the withdrawal score is essential because 
pharmacological treatment and discharge decisions are made based on the infant’s assessed score 
(D'Apolito, 2014).  Infants are recommended to be assessed using the instrument every 3-4 hours 
according to their feeding schedules (Finnegan, 1990; Finnegan & Kaltenbach, 1992).  
Pharmacological Treatment of NAS 
There is still considerable variability regarding the pharmacological management of 
infants with NAS. Despite continuing research, there is currently no standardized national 
pharmacological treatment guidelines established for this high-risk population. Drugs used to 
treat this population have included methadone, morphine, buprenorphine, tincture of opium, 
alone or in combination with adjunctive therapies such as phenobarbital and clonidine (Hudak & 
Tan, 2012). The 2012 AAP guidelines recommend that pharmacological management of infants 
with NAS due to prenatal exposure to an opioid include treatment with an opiate derivative 
(Hudak & Tan, 2012). According to the 2012 AAP recommendations, morphine and methadone 
are considered first line therapy, while phenobarbital and clonidine are considered adjunctive 
therapies for NAS infants with persisting CNS signs despite treatment with an opiate derivative 
(Hudak & Tan, 2012). The pharmacological management of infants with NAS is indicated when 
the non-pharmacological interventions alone have not been able to relieve moderate to severe 
signs of acute drug withdrawal (Hudak & Tan, 2012). The 2012 AAP guidelines also caution 
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against the unnecessary pharmacological treatment of infants with NAS which can prolong drug 
exposure and increase the length of hospitalization, posing significant risk to maternal-infant 
bonding (Hudak & Tan, 2012).   
Opioids.  Osborn, Jeffery, and Cole (2010a) conducted a meta-analysis of all randomized 
and quasi-randomized studies on opioids in the treatment of NAS. Nine studies were critiqued 
and appraised by the authors to assess the effectiveness and safety of using an opioid compared 
to a sedative or non-pharmacological intervention for the treatment of NAS due to withdrawal 
from opiates as part of this meta-analysis (Osborn et al., 2010a). The authors concluded that due 
to the methodological limitations of the studies reviewed, there was not enough evidence to 
determine if one opioid is better than another (Osborn et al., 2010a). They also could not 
recommend a specific algorithm for treating infants with NAS (Osborn et al., 2010a). Finally, 
Osborn et al. (2010a) suggest that opioid treatment should be limited to NAS infants exposed to 
opioids in utero. 
More recently, the safety and efficacy of methadone compared to morphine has been 
studied in several randomized clinical trials (Brown, Hayes, & Thornton, 2015; Davis, et al., 
2018). Brown, et al. (2015) reported that of the 198 opioid exposed infants (methadone and 
buprenorphine) who were admitted to the NICU during the study period, 94 patients met the 
treatment requirements, and 16 were excluded because of identified life threatening clinical 
conditions, congenital anomalies, or were unavailable for consent. Seventy eight were 
determined to be eligible however, 47 mothers declined consent because they wanted to know 
what medication would be used to treat the infant (Brown et al., 2015). Thirty one were 
randomized, resulting in 15 in the methadone group and 16 in the morphine group. The results 
revealed that length of opioid treatment was shorter for the methadone group (median = 14 days) 
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as compared to the morphine group (median = 21days) which was statistically significant (p = 
0.008) (Brown et al., 2015). The small sample size from one NICU pose limitations to the 
generalizability of the study findings. Similarly, Davis et al. (2018) conducted a randomized, 
double-blind, intention to treat trial to compare the safety and efficacy of methadone and 
morphine for the treatment of infants with NAS. The investigators consented 183 opioid 
dependent mothers and identified 117 infants who required treatment for NAS. Fifty nine infants 
were randomized to the methadone group and 58 were randomized to the morphine group (Davis 
et al., 2018). The methadone group was reported to have a 14% decreased length of stay (relative 
number of days attributable to NAS decreased by 2.7 days). In addition, the length of treatment 
was decreased by 16% (2.3 days) in the methadone group when compared to the morphine 
treated group (Davis et al., 2018). There were 13 adverse events which were similar between 
groups which included oxygen desaturation, shallow respirations, vomiting, lethargy, and low 
temperature. The protocol was amended to allow for faster weaning based on the observed 
adverse events. The study was limited by an inability to meet targeted recruitment goals (Davis 
et al., 2018).  
Although the emerging evidence suggests that methadone compared to morphine may 
result in reduced in length of stay and length of treatment, Burke and Beckwith (2017) completed  
a small retrospective study and reported lower Bayley Scales of Infant and Toddler 
Development-Third Edition (Bayley III) mean composite cognitive and motor scores in 
methadone-treated infants compared to those treated with morphine. Developmental outcomes 
were assessed in 36 infants treated for NAS (17 treated with methadone and 19 treated with 
morphine). The infants were assessed using the Bayley III. The infant scores in the cognitive, 
language, and motor domains were examined for comparison. The infants in the morphine group 
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were noted to have statically higher scores in both the cognitive (91.3 vs. 83, p = 0.3410) and 
total motor composite scores (96.3 vs. 89.6, p = 0.0149) (Burke, & Beckwith; 2018).  
Buprenorphine. Buprenorphine is a long acting synthetic opiate which has been shown 
to be safe in the treatment of opioid addicted pregnant women (Gaalema et al., 2012; Shainker, 
Saia, & Lee-Parritz, 2012). The use of buprenorphine to treat withdrawal in infants with NAS is 
the focus of current neonatal studies because the drug is known to have less respiratory 
depression when compared to other opioid agonists (Kraft & van den Anker, 2012). Kraft et al. 
(2008) conducted a randomized, open-label, active-control study of sublingual buprenorphine for 
the treatment of opiate withdrawal to determine the safety and efficacy of buprenorphine. The 
sample consisted of 26 infants who were randomized to treatment or control groups. Thirteen 
infants were randomized to receive oral buprenorphine and 13 infants were randomized to 
receive neonatal opium. The modified Finnegan scores of the infants in both groups were 
followed to measure the ability of the drugs to control withdrawal symptoms. The authors 
reported that sublingual buprenorphine at a dose of 13.2 to 39.0 mcg/kg/per day, administered in 
3 divided doses which represented a higher maximum starting, higher maximum daily dose, and 
higher titrating dose, was safe. Kraft et al. (2011) completed a similar study to determine the 
safety and effectiveness of buprenorphine compared to oral morphine in the treatment of infants 
with NAS born to mothers with opioid dependence. Term infants (n = 24) requiring 
pharmacological treatment for NAS were randomized (n = 12) to receive buprenorphine and (n = 
12) to receive neonatal opium. They reported that sublingual buprenorphine at a dose of 15.2 to 
60 mcg/kg/per day, administered in 3 divided doses which represented a higher maximum 
starting, higher maximum daily dose, and higher titrating dose, was safe. After completing a 
second study, Kraft and van den Anker (2012) combined the results of the first study with the 
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results of the second (n = 50) and again reported that buprenorphine can be safely administered 
to full term infants who have been exposed to opioids (Kraft et al., 2008; Kraft & van den Anker, 
2012).   
More recently a prospective, double blind, RCT was conducted to compare the outcomes 
of 78 eligible infants treated for NAS with methadone compared to morphine (Brown, Hayes, & 
Thornton, 2015). The investigators reported that 47 of the mothers declined consent because they 
wanted to know what medication was going to be used to treat their infant. Thirty one infants 
were randomized, 15 in the methadone group, and 16 in the morphine group. The length of 
opioid treatment was noted to be significantly shorter (p = 0.008) in the methadone group (a 
median of 14 days) when compared to the morphine group (who were treated a median of 21 
days) (Brown, et al., 2015). The efficacy of methadone vs. morphine was also compared in a 
more recent RCT with a larger sample size of 116 analyzed infants treated for NAS (Davis, et al., 
2018). The infants were randomized (n = 59) to the methadone group and n = 58 to the morphine 
group. The length of stay was decreased in the methadone group (decreased by a mean of 2.9 
days) which was statistically significant (p = 0.046) and length of treatment (decreased by a 
mean of 2.3days) (Davis, et al., 2018). Despite these encouraging findings, Burke and Beckwith 
(2017), after completing a retrospective chart review to compare the neurodevelopmental 
outcomes using the Bayley Scales of Infant and Toddler Development- Third Edition (Bayley 
III) of 36 infants treated for NAS with methadone (n = 17) vs. morphine (n = 19) cautioned that 
the infants in the methadone group had lower mean cognitive composite (91.3 vs. 83; p = 
0.03410) and lower mean total motor composite scores (96.3 vs. 89.6; p = 0.0149) when 
compared to the morphine group. 
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Additional large scaled randomized controlled trials are necessary to determine which 
opioid derivatives are the most efficacious and pose the least possible risk to the infant. The most 
commonly used opioids (methadone, morphine, buprenorphine, alone and in combination with 
phenobarbital and clonidine) need to be tested side by side in multiple arms of methodologically 
sound randomized controlled trials to provide replicable empirical evidence, possibly leading to 
the development of standardized medication treatment protocols for this high-risk population of 
NAS infants. Infants with NAS who have been exposed prenatally to opioids and 
benzodiazepines must be included in these studies as this sub-population of high-risk infants has 
historically been excluded from previous drug studies and represents an increasing number of 
infants.   
Second-line drugs (phenobarbital and clonidine). According to the 2012 AAP 
guidelines, second-line drugs are indicated when the NAS infant has persisting signs of 
withdrawal despite adequate treatment with an opioid derivative such as the presentation often 
seen with NAS infants with prenatal opioid and benzodiazepine exposure (Hudak & Tan, 2012). 
Phenobarbital is preferred over diazepam to reduce persisting CNS related symptoms in infants 
being treated with an opioid for NAS (Osborn, Jeffery, & Cole, 2010b). There is no evidence to 
support the use of chlorpromazine in the treatment of infants with NAS (Osborn et al., 2010b). 
Clonidine is being used more commonly in NICUs as an adjunct medication to treat infants with 
NAS displaying persisting CNS signs. Agthe et al. (2009) conducted a randomized controlled 
trial to test the effectiveness of clonidine and tincture of opium, compared to a placebo and 
tincture of opium, in reducing the total number of days of required treatment on tincture of 
opium for infants with NAS exposed to prenatal heroin and methadone. Forty infants were 
randomized to the treatment group and 40 infants were randomized to the control group. The 
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investigators reported that the median length of opioid treatment was 27% shorter in the 
clonidine plus opioid group (Agthe et al., 2009). Surran et al. (2013) conducted a prospective 
randomized controlled trial to compare the length of treatment of NAS infants treated with 
morphine plus clonidine vs. those treated with morphine plus phenobarbital. The study found 
that infants in the clonidine plus morphine treated group (n = 34) required less total treatment 
days without requiring an increase in their morphine dose (Surran et al., 2013). Infants in the 
phenobarbital plus morphine group (n = 34) required treatment longer, an average of 3.8 months, 
with a range of 1-8 months, but were discharged home from the hospital sooner (Surran et al., 
2013). The cost savings associated with discharging infants with NAS sooner on phenobarbital 
need to be carefully weighed against the potential risk of poor neurodevelopmental outcome 
related to prolonged exposure to the medication. More recently, Gullickson, Kuhle, & Campbell-
Yeo (2018) conducted a retrospective study to compare the length of treatment in infants treated 
for NAS with (n = 22) morphine monotherapy vs. (n = 100) treated with morphine and clonidine. 
The infants in the morphine combined with clonidine group were noted to have a longer length 
of treatment (p = 0.004) and higher peak morphine doses were also observed (p = 0.045). Future 
studies need to focus on testing standardized treatment and weaning protocols for both 
phenobarbital and clonidine to reduce unnecessary variation in the lengths of treatment and risks 
associated with prolonged exposure. Studies are also needed to determine the long term risks 
associated with clonidine in this high-risk population.  
Non-pharmacological Treatment of NAS 
Infants with NAS are known to have difficulty with sensory integration, as even small 
amounts of stimulation may be overwhelming for these infants to manage. State regulation and 
sleep and wake cycles are frequently disorganized in this high-risk population of infants (Sublett, 
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2013; Velez & Jansson, 2008). Non-pharmacological interventions are therefore frequently used 
prior to pharmacological treatment to help the infant with NAS cope with all the sources of 
environmental stress they may experience (Sublett, 2013; Velez & Jansson, 2008). 
Reduction of environmental stimuli. Two descriptive case series studies suggest that 
interventions designed to reduce environmental stimuli such as providing a dark quiet 
environment, private patient rooms, and clustered care are all therapeutic interventions that can 
provide support for infants with NAS (Green & Goodman, 2003; Marcellus, 2007). Additional 
interventions such as gentle handling, swaddling the infant, positioning the infant on their back 
or side in a fetal position, or providing containment are also frequently used clinical 
interventions employed to decrease hyper-arousal and tremors in this population (Green & 
Goodman, 2003; Marcellus, 2007). 
Holding, Rocking, & Massage. Holding and gentle slow vertical rocking has been 
suggested to provide soothing effects in promoting maternal-infant bonding and foster calm 
interactions between infants experiencing acute drug withdrawal and their opioid-dependent 
mothers (Marcellus, 2007; Velez & Jansson, 2008). White-Traut et al. (2002) conducted a 
randomized controlled trial to compare the responses of non-exposed and drug exposed infants to 
an intervention which included auditory, tactile (massage), eye-to-eye contact and vertical 
rocking. The treatment group in this study received an integrated intervention that included 
twice-daily 15-minute stimulation using the ATVV (auditory, tactile, visual, and vestibular-
rocking stimulation) (White-Traut et al., 2002). Infant behavioral state and pulse rate were 
measured in the two groups. The study found that the ATVV intervention promoted normal 
physiologic and behavioral function in the drug-exposed infants (White-Traut et al., 2002).   
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Non-nutritive sucking, & laser acupuncture. Providing pacifiers for non-nutritive 
sucking to promote infant self-soothing behavior and decrease skin excoriation from frantic, 
erratic infant movements was shown to be a therapeutic intervention to support infants 
experiencing acute drug withdrawal in two case series studies (Green & Goodman, 2003; Velez 
& Jansson, 2008). Wolfgang, et al. (2015) conducted a prospective, randomized controlled, 
blinded, single-center trial to determine if infants randomly allocated to laser acupuncture 
(combined with pharmacological therapy of morphine and phenobarbital) or control group 
(pharmacological therapy alone) would reduce the duration of treatment required in NAS infants. 
The sample consisted of 28 infants with NAS, 14 were randomized to the treatment group (laser 
acupuncture combined the pharmacological therapy), and 14 were randomized to the control 
group (pharmacological therapy alone). Infants born to mothers who self-reported poly drug use 
were excluded from participation in the study. The investigators reported that the infants in the 
treatment group (who received a combination of laser acupuncture and pharmacological 
management) had shorter duration of oral morphine treatment when compared to infants in the 
control group (pharmacological management only). The acupuncture group was noted to require 
oral morphine for 28 days vs. 39 days in the control group. The small sample size posed a 
limitation to the study findings (Wolfgang, et al., 2015). 
Water bed, rocking bed, vs. standard crib. Infants with NAS positioned on non-
oscillating water beds were shown to require less medication to control their withdrawal 
symptoms and demonstrated a better pattern of weight gain when compared to the control group 
(Oro & Dixon, 1988). D'Apolito (1999) conducted a repeated measure experimental study of 14 
infants with NAS, who were randomized to treatment or control groups, to determine the effect 
of a rocking bed vs. a standard bed on reducing withdrawal symptoms. The 14 infants in the 
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study were prenatally exposed to methadone and other illicit drugs (D'Apolito, 1999). The study 
results suggested that the infants in the intervention group who were placed in the rocking beds 
became hyper-stimulated and were not able to sleep, had higher withdrawal scores, and sub-
optimal neurodevelopmental behavior at 7-days compared to infants in the control group 
(D'Apolito, 1999). The author concluded that the rocking bed was over stimulating to NAS 
infants during the acute withdrawal period and did not recommend the use of this intervention in 
this population without further study (D'Apolito, 1999). The type of bed and positioning of 
infants with NAS needs further empirical testing, especially in light of the campaign to reduce 
sudden infant death which recommends infants be placed on their backs, on firm bedding, 
offered a pacifier, avoid overheating the infant, and not have any soft toys or bedding in their 
crib. 
Breastfeeding. Exclusive breastfeeding is recommended for infants for the first 6-months 
of life by the AAP, unless there are known contraindications, because of the overwhelming 
evidence of the benefits it provides which include reduced health related costs, protection from 
infectious diseases, asthma, reduced risk of SIDS, reduction in the incidence of type 1 and type 2 
diabetes, and higher performance on tests of cognitive development (Gartner et al., 2005).  
Breastfeeding also provides benefits for the mother including reduced incidence of postpartum 
bleeding, earlier return to pre-pregnancy weight, decreased risk of breast cancer and ovarian 
cancer and possibly decreased risk of hip fractures and osteoporosis (Gartner et al., 2005). 
Breastfeeding also promotes mother infant bonding and reduces maternal depression (Pritham, 
2013). The 2012 AAP guidelines no longer restrict breastfeeding in mothers of infants 
experiencing acute drug withdrawal provided they are negative for human immunodeficiency 
38 
 
virus (HIV), illicit drugs, follow the established guidelines for minimal alcohol consumption, and 
are enrolled in a supervised drug maintenance program (Hudak & Tan, 2012).   
Methadone and buprenorphine levels in breastmilk are low regardless of maternal dose, 
and are determined to be safe to be fed to infants with NAS (Jansson et al., 2008; Jansson, Velez, 
& Harrow, 2004). McQueen, Murphy-Oikonen, Gerlach, and Montelpare (2011) completed a 
retrospective chart review and found that in a sample of 28 predominantly breastfed infants being 
treated with methadone for NAS required less withdrawal scores to be taken, and had lower 
mean scores when compared to infants who received partial breastmilk feedings and formula. 
Suggesting that breastfeeding compared to formula feeding may lower the severity and duration 
of NAS (McQueen et al., 2011). Pritham, Paul, and Hayes (2012) conducted a similar 
retrospective descriptive study and found an association between infants experiencing acute drug 
withdrawal who were breastfed only, compared to formula-fed and neonates who received partial 
breastmilk and formula feedings, and a decrease in the rate of treatment for withdrawal in both 
methadone and buprenorphine prenatally exposed neonates. The study provides some evidence 
that breastfeeding should be encouraged in this high-risk population to shorten the length of stay 
(Pritham et al., 2012).   
The literature suggests that there are many potential barriers to opioid dependent mothers 
initiating and continuing breastfeeding, especially in the NICU environment. Proposed strategies 
to promote breastfeeding include providing current, and accurate information on breastfeeding, 
ensuring knowledgeable lactation consultants are readily available, providing kangaroo (skin-to-
skin) care, and providing rooming-in options to keep the mother and infant together (Pritham, 
2013). O'Connor, Collett, Alto, and O'Brien (2013) completed a retrospective chart review for all 
infants born to opioid dependent mothers treated in an integrative buprenorphine maintenance 
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program between 2007 and 2012. Sixty five mothers who enrolled in the program decided to 
breastfeed. The comprehensive program included obstetrical and addiction medicine specialist 
care and a 1-hour per week counseling session (O'Connor et al., 2013). The group was facilitated 
by a psychologist with advanced training in addiction. Physicians, practitioners, social workers, 
obstetric nurses, and lactation specialists frequently attended the group. The program did not 
have a specific curriculum, the topics of discussion were frequently determined by the questions 
raised by the mothers, however, the clinicians facilitating the groups ensured that breastfeeding 
education and treatment options for infants with NAS were frequently discussed (O'Connor et 
al., 2013). Of the 65 mothers enrolled in the sample, 66% were still reported to continue 
breastfeeding at 6-8 weeks postpartum (O'Connor et al., 2013). In contrast, Wachman, Byun, and 
Philipp (2010) conducted a retrospective chart review of opioid dependent mothers who 
delivered at a designated Baby-Friendly-Hospital in Boston Medical Center July 2003-January 
2009 and identified 276 dyads. Sixty-eight percent of the mothers identified were determined to 
be eligible to breastfeed, and of those mothers, only 24% actually breastfeed to some extent 
during their NAS infant’s hospitalization (Wachman et al., 2010).  Sixty percent of the mothers 
who initiated breastfeeding discontinued breastfeeding after an average of 5.88 days (Wachman 
et al., 2010). The differences in breastfeeding initiation and duration between these two studies 
suggests that an integrated comprehensive program targeting the common barriers to 
breastfeeding in this population may be more successful. Future studies need to focus on how 
best to educate narcotic addicted mothers on the benefits of breastfeeding their infants and test 
strategies to determine which strategies or combination of strategies are most successful in 
promoting and sustaining breastfeeding in this high-risk population. 
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Rooming-in.  Newman et al. (2015) conducted a retrospective chart review to explore the 
effect of a rooming-in program designed to provide opioid-dependent mother-infant dyads with 
uninterrupted contact with their infants. The study suggested that there was a reduction in the 
proportion of infants requiring pharmacotherapy and their average length of hospital stay was 
reduced (Newman et al., 2015). Rooming-in programs have been shown to mitigate the 
relationship between maternal methadone dosage and the need to treat the infant for NAS 
(Hodgson & Abrahams, 2012). Rooming-in programs have also been suggested to be a safe 
alternative to the current standard of care that separates the dyad and promotes maternal infant 
attachment and breastfeeding in this high-risk population (Hodgson & Abrahams, 2012; 
Newman et al., 2015). 
Home-based weaning. Home-based weaning strategies have been proposed as a cost 
effective alternative to traditional NICU hospitalization for the treatment of infants with NAS 
and as approach to promote parent infant bonding. However, the potential benefits of home-
based weaning must be balanced against the potential safety risks for the infant (need for 
protective services and foster care placement related to neglect or abuse). Careful selection of 
mother infant dyads using strict criteria is critical to the success of home based weaning 
programs, along with ongoing outpatient monitoring of the safety of the infant. Multiple 
retrospective chart reviews have been conducted to evaluate the safety and efficacy of the 
traditional NICU inpatient only weaning approach compared to a combined inpatient and 
outpatient weaning strategy (Brackets et al, 2012; Smirk, Bowman, Doyle, & Kamlin, 2014). 
Brackets et al. (2012) reported that in carefully selected infants, combined inpatient/outpatient 
weaning compared to traditional NICU inpatient only weaning was associated with reduced 
hospital length of stay, total methadone treatment duration, and increased rates of breastfeeding. 
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The investigators reported that breast feeding rates were improved, 24% combined group vs. 8% 
in the traditional group, (p < .05). In addition, the length of hospital stay decreased ranging from 
25 + 15 days for the traditional group, compared to 13 + 5 days for the combined group. The 
total duration of methadone treatment was longer 37 + 20 days in the traditional group vs. 21 + 
14 day, (p = < 0.001) in the combined group. The average cost for an infant in the combined 
group was $13 729, compared to $27 546 for an infant in the NICU hospitalized traditional 
group. The investigators reported an estimated cost reduction of $635 000 in a 2 year period. In 
addition, patient safety data revealed that there were no infant deaths. However, two infants in 
the combined group required a referral to child protective services for alleged neglect or abuse. 
The readmission rates were reported to be comparable between the two groups (5% in the 
traditional group, vs. 7% in the combined group) (Brackets, et al., 2012) 
Smirk et al. (2014) reported similar findings based on data from a retrospective chart 
review of 118 infants with NAS treated for in utero exposure to opioids (methadone or 
buprenorphine). Of the 118 infants, 38 were carefully selected for home based weaning and 80 
were weaned as traditional NICU inpatients. The investigators reported that the infants in the 
home based weaning group had decreased length of hospital stay (mean 19 days vs. 41 days in 
the traditional combined group). The mothers in the home based weaning group had reportedly 
higher rates of breastfeeding at the time of discharge (45% vs. 22% in the traditional inpatient 
group). In addition, there were no increased incidence of patient safety issues (need for child 
protective services and foster care placement) or serious adverse events noted between the two 
groups (Smirk, et al., 2014). 
Summary. In summary, the empirical evidence related to the care and treatment of 
infants with NAS and their mothers was reviewed.  The review of the literature revealed four 
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relevant substantive themes related to this proposed research study including: definitions of 
NAS, screening and measurement instruments for NAS, pharmacological management of infants 
with NAS, and non-pharmacological management of infants with NAS.  Critique and appraisal 
of the existing evidence was provided and revealed critical gaps in the existing literature 
including a lack of national standards and guidelines for pharmacological management of the 
infant with NAS, limited empirical evidence to support the non-pharmacological interventions 
commonly used in this high-risk population, and lack of abstinence scoring instruments with 
prior evidence for the validity and reliability of scores generated in infants greater than 28 days 
of age.   
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CHAPTER THREE: 
METHODS 
 
This chapter presents the study methods. It is organized by institutional approvals, 
funding, design, setting, sample, sampling plan, population, theoretical and operational definition 
of terms, measures, and study procedures. The chapter concludes with a detailed description of 
the data analysis plan according to the specific study aims. 
Institutional Approvals 
Approval for the study was obtained from the Johns Hopkins All Children’s Hospital 
(JHACH) and the University of South Florida (USF) Social and Behavioral Institutional Review 
Boards (see Appendix B).   
Funding 
 The study was supported by a monetary award from the JHACH Novice Nurse 
Researcher: Nursing Excellence Guild Fund. 
Design 
The proposed study was a retrospective chart review of infants less than and greater than 
28 days of life with a primary diagnosis of NAS (hospitalized in the NICU between January 1, 
2010-May 18, 2018).  
Setting 
The study was conducted at JHACH, a 97 bed level IV NICU, located in St. Petersburg, 
Florida. 
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Sample/Sampling Plan 
The partial medical records of an estimated 300 infants diagnosed with NAS who had 
documented modified-FNAST scores and were hospitalized in the NICU at JHACH between 
January 1, 2010 and May 18, 2018 and meet the inclusion criteria (and did not have any 
exclusionary criteria) comprised the convenience sample.  
Population (Inclusion/Exclusion Criteria) 
To meet the eligibility criteria the infants must have been born to an opiate-dependent 
mother, admitted to the NICU with a primary diagnosis of NAS (within day of life 3) and 
required pharmacological management. NAS infants who had life threatening conditions in 
which NAS was only a secondary diagnosis, were discharged from other in patient units, or were 
premature (less than 37 weeks), were excluded from participating in the study.  
The standard of care for infants with NAS was to assess the severity of drug withdrawal 
using the modified-FNAST every 3-4 hours post feeding. Infants diagnosed with NAS at JHACH 
had an average length of stay of 30.2 days (based on JHACH internal data from January 2013-
Janary 2015). Thus, the number of assessments for each infant was expected to yield 181-242 
assessments. There were 122 infants in 2014 identified as having NAS. Assuming there were at 
least that many in 2015, the estimated number of infants with NAS would be about 610 infants. 
This would yield an approximate total of 110,532-147,376 assessments. Given that 261 of the 
309 (84%) total infants hospitalized with the diagnosis of NAS (based on JHACH internal data 
from January 2013-Janary 2015) were greater than 28 days of life, it was anticipated that we 
would be able to obtain an adequate number of modified-FNAST scores to perform a meaningful 
factor analysis. The modified-FNAST assessments for each NAS infant who met the established 
inclusion criteria was evaluated independently, as was the process of Factor Analysis. 
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Theoretical and Operational Definition of Terms 
Theoretical Definition of Maternal Opioid Dependence. NAS is a consequence of in 
utero exposure to drugs from their opioid-dependent mother (Hudak & Tan, 2012; Kocherlakota, 
2014). Expectant management for the opioid dependent pregnant women includes opioid 
maintenance therapy with methadone or buprenorphine (Hudak & Tan, 2012). The onset and 
severity of NAS is dependent on the main substance the infant is withdrawing from, the unique 
combination of substances the infant was exposed to, and the gestational age of the infant. The 
short half-life of opiates is thought to be responsible for the rapid onset of the symptoms 
characteristic of NAS, which usually are noted within 72 hours after birth in infants born to 
mothers who are opioid-dependent (Cramton & Gruchala, 2013). In contrast, methadone exposed 
newborns present with symptoms 2-6 days after birth, and sedative-hypnotics (benzodiazepines 
and barbiturates) exposed newborns which may not manifest symptoms of NAS until a week or 
more after birth (Cramton & Gruchala, 2013). Polysubstance abuse (opioids and benzodiazepines 
in particular) during the pregnancy has been shown to produce more severe symptoms of 
withdrawal when compared to exposure to a single substance (Cramton & Gruchala, 2013). The 
dose of opiate the infant was exposed to in utero does not seem to correlate with the severity of 
NAS (Thajam et al., 2010).  
Operational Definition of Maternal Opioid Dependent Mother. For the purposes of 
this study, opioid-dependent mothers were operationally defined as a mother who has a 
documented history of opioid dependency. The history of maternal opioid dependency was 
confirmed by documentation in the admission history of the EMR of the newborn and urine drug 
screen. 
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Theoretical Definition of NAS. NAS is the term used to describe the specific acute drug 
withdrawal pattern observed in infants born to opioid-dependent mothers. NAS is characterized 
by a typical pattern of withdrawal behaviors involving central nervous system (CNS) related 
signs (tremors, increased muscle tone, seizures and high-pitched cry), respiratory system related 
signs (tachypnea, and retractions), gastrointestinal system related signs (poor feeding, vomiting, 
diarrhea, and uncoordinated and excessive sucking), and autonomic system related signs 
(mottling, nasal stuffiness, excessive yawning, sneezing, and temperature) (Finnegan et al., 1975; 
Hudak & Tan, 2012; Kocherlakota, 2014). The American Academy of Pediatrics (AAP) 
recommends that the infants at risk for NAS be monitored and the severity of drug withdrawal be 
measured using an instrument with empirical evidence to support the validity and reliability of 
the scores obtained in this population (Hudak & Tan, 2012). 
Operational Definition of NAS. For the purposes of this study, an infant with NAS was 
operationally defined as a term infant who was exposed to opiates prenatally, presented with 
signs of acute drug withdrawal and was diagnosed as having abstinence syndrome requiring 
pharmacological treatment and hospitalization in the NICU at JHACH. The diagnosis of NAS 
was confirmed by documentation in the admission or discharge notes of the electronic medical 
record (EMR) of the newborn and confirmed by urine and/or meconium drug screen when 
available.  
Measures 
Modified-FNAST Scores. The severity of drug withdrawal was quantified as the 
modified-FNAST scores of the infant. The assessments were documented in the EMR every 3-4 
hours by the bedside nurse. Each of the 21 items in the modified-FNAST were scored, as well as 
the total score.  
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Demographic Instrument. A demographic instrument was created specifically for this 
study to collect the maternal and infant data required for analysis of the specific study aims. 
Study Procedures 
Data Collection. After obtaining IRB and the necessary administrative approvals, the 
data was extracted from the electronic medical record (EMR) of the eligible infants in order to 
measure the achievement of the specific study aims. Based on the evaluation from the JHACH 
DataLine Senior IT representative it was only possible to extract a portion of the infant’s 
demographic data de-identified from the data warehouse. Therefore, the remaining demographic 
data on the infant including, all drugs used to treat NAS, max total dose of each drug prescribed, 
and the duration of pharmacological management for each drug used to treat the infant was 
manually extracted by the study team. Demographic data on the mother including age, race, 
ethnicity, education, significant mental health and trauma history, significant drug history, and 
urine drug screen result were manually extracted using the patient medical record number. The 
maternal demographic data was manually extracted from the infant’s medical record (provider 
admitting note and/or social services note) and entered de-identified directly into REDCap 
(coded using the unique participant ID number) by the PI and co-investigators who had 
completed the necessary protection of human subjects training.  
The complete list of demographic data collected on the infant included the medical record 
number, birth weight, day of life, gender, gestational age, verification of admitting diagnosis of 
NAS, all modified-FNAST total scores, individual 21-item modified-FNAST scores and total 
scores for each assessment, list of drugs used to treat NAS, duration of pharmacological 
management for drug used to treat NAS, maximum doses of each specific drug used to treat 
NAS, date of discharge, urine and meconium drug screen results. These data were collected on 
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all infants admitted to the NICU with a diagnosis of NAS as part of the standard of care. The 
portion of the data extracted from the infant’s medical record by the DataLine (from the data 
warehouse) was combined with the data manually extracted. The combined data was exported as 
an excel spread sheet file that was uploaded directly into SPSS coded only with the participant 
unique study ID number for analysis. The de-identified SPSS file was stored in a secure 
password protected Johns Hopkins (JH) and USF boxes accessible only by the study team 
members. 
Protection of Human Subjects 
Potential Risk to the Participants. This was a minimal risk study (retrospective chart 
review) involving data extraction, however, there was a risk for breach of confidentiality if the 
temporary key code that linked the patient identification number to the unique identifier of the 
patient was compromised. There were no experimental procedures or interventions implemented 
as part of this study. 
Potential Benefit to the Participants. There were no direct benefits to participants and 
society however, this retrospective study may provide empirical evidence to promote the 
development of a reliable and valid instrument for assessing abstinence in infants greater than 28 
days old in the future. The potential future benefit outweighed the risk for this minimal risk 
study. 
Alternatives to Participation. The alternative to participation was no participant 
involvement in the study (no extraction of partial medical records). 
Measures to Protect Human Subjects. To protect the confidentiality of the human 
subjects in this research study, all patients were assigned a unique patient identifier number. In 
order to extract the retrospective data from the EMR, a waiver of consent and HIPAA was 
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requested from the IRB. A waiver of consent and HIPAA was necessary because the study team 
did not have the necessary contact information to obtain consent from the eligible participants. 
The demographic data on the mother was manually collected by the PI and study team members 
who had all completed the required protection of human subjects training. The maternal 
demographic data and infant data fields unavailable from the data warehouse were then entered 
into a secure REDCap data base, coded using only the unique patient identifier number, and later 
downloaded into the SPSS file for analysis. A portion of data on the infant was extracted from 
the infant’s medical record by the DataLine (from the data warehouse) as an excel spread sheet 
file which was uploaded directly into SPSS coded only with the participant unique study ID 
number. The SPSS file was stored in secure password protected JH and USF boxes accessible 
only by the study team members. 
In order to accurately identify the eligible NAS infants and manually extract the maternal 
demographic data, a temporary key code was maintained to link the medical identification 
numbers of the infant to the unique identifier code. This temporary key code was stored in a 
separate password protected computer file from the SPSS data file in the JH and USF boxes that 
was only accessible by the PI and the study team members. The key code was destroyed once all 
the data had been collected and analysis was completed. Only de-identified data was retained for 
five years as required by the IRB.  In addition, only the de-identified, aggregate data will be 
disseminated in any future posters, podium presentations, and manuscripts, which may result 
following the completion of this study. 
Data Analysis Plan 
Data analysis was performed using the statistical package for the social sciences (SPSS) 
version 24.0 (IBM, Armonk, NY). 
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Aim #1. To determine which of the 21 items in the modified-FNAST are most predictive 
of the need for pharmacological treatment in infants greater than 28 days of life diagnosed with 
NAS, Logistic Regression was used (Tabachnick, & Fidell, 2013). 
Aim #2. To explore the interrelationships among the 21 items of the modified-FNAST to 
determine the underlying structure in infants less than 28 days of life diagnosed with NAS 
experiencing acute drug withdrawal. Exploratory Factor Analysis was used (Tabachnick, & 
Fidell, 2013). 
Aim #3. To explore the interrelationships among the 21 items of the modified-FNAST to 
determine the underlying structure in infants greater than 28 days of life diagnosed with NAS 
experiencing acute drug withdrawal. Exploratory Factor Analysis was used (Tabachnick, & 
Fidell, 2013). 
Aim #4. Comparison was made between the underlying structures of the 
interrelationships of the items of the modified-FNAST as determined by the EFA in infants less 
than and greater than 28 days of life diagnosed with NAS experiencing acute drug withdrawal.  
AIM #5. The relationship between the medications used to treat infants for NAS and the 
longitudinal trajectory of the Finnegan scores was described. Descriptive Analyses were used to 
explore the relationship between the means of the total Finnegan scores (on day 1, 3, 7, and then 
weekly) and the medications used to treat the infants in the sample. A repeated measures Mixed 
Effect Model was used to compare the mean Finnegan scores between the different medication 
groups (Tabachnick, & Fidell, 2013). The trajectory of the mean Finnegan scores and the 
relationship between the medication groups was reported in run charts using excel. 
Exploratory factor analysis was used in the analysis of aims 2-4. Exploratory factor 
analysis of the average individualized and total modified-FNAST scores of infants less than and 
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greater than 28 days of life were performed on day 1, 3, 7, then weekly, and on the day of 
discharge to determine the underlying dimensions and explore the similarities and differences 
between the groups (see Table 2). 
Exploratory Factor analysis is a statistical method used to assess construct validity (Polit, 
2010; Tabachnick, & Fidell, 2013). Factor analysis is a measure to assess various dimensions or 
subcomponents of a phenomena of interest to empirically justify these dimensions or factors 
(Polit, 2010; Tabachnick, & Fidell, 2013). This process helps to understand the most important 
patterns of a phenomena (Polit, 2010).  
Table 2. Factor Analysis Plan (Pallat, 2013; Polit, 2010; Tabachnick, & Fidell, 2013) 
Exploratory factor analysis of the average individualized and total modified-FNAST scores of infants less than 
and greater than 28 days of life will be performed on day 1, 3, 7, then weekly, and on the day of discharge to 
determine the underlying dimensions and explore the similarities and differences between the groups. The factor 
analyses will include the following steps each time the analyses is performed. 
Step 1. Assessment of 
the Suitability of the 
Data for factor analysis 
 
Step 2. Factor Extraction (Principal 
Components Analysis & Principal Axis 
Factoring) 
 
Step 3. Factor Rotation and 
Interpretation 
 
Sample size- >150 
Strength of the 
Relationship of the 
Items of the modified- 
FNAST 
If there are few 
correlations > .3 a 
factor analysis may 
not be appropriate. 
Bartlett’s chi-
square test 
Kaiser-Meyer-
Olkin (KMO) 
Measure of 
Sampling 
Adequacy 
Goal: obtain a solution with the smallest 
number of factors that can be used to 
represent the interrelationships among a set 
of variables, and explain as much of the 
variance as possible. 
*The Components Matrix, Pattern, & 
Structure Matrixes from SPSS will be 
reviewed and the following analyses will be 
performed: 
Kaisers Criteria- only factors with an 
eigenvalue above 1 will be retained. 
Catell’s (1966) Scree Test- plot each of the 
eigenvalues of the factors by inspecting the 
plot produced by SPSS and identify the area 
above the elbow, and retain only factors 
above the elbow. 
Horn’s (1965) Parallel Analysis- involves 
comparing the size of the eigenvalues with 
those obtained from a randomly generated 
data set of the same size. Using this 
approach, only eigenvalues that exceed the 
corresponding values from the random data 
set are retained for the final solution. This 
test has been shown to be the most accurate 
of the three. 
 
Goal: Rotation does not alter the 
underlying solution. It presents the 
patterns of loadings in a manner that 
is easier to interpret by depicting 
which variables cluster together. The 
goal according to Thurstone (1947) is 
to obtain a simple solution (is when 
you have high factor loading on only 
one factor).  
     Ideally, the factor loadings are as 
close to 1.00 as possible for the 
variables aligned with a factor, and 
the loadings are as close to 0.00 as 
possible for variables not aligned 
with the factor. 
Orthogonal Rotation- assumes that 
the factors are not correlated. 
Generates a factor solution that is at a 
90 degree angle. The most widely 
used orthogonal rotation is Varimax 
rotation. Since the factors are known 
to be correlated this approach would 
not be appropriate. 
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Table 2. Factor Analysis Plan Continued 
 
  Oblique Rotation- assumes that the 
factors are correlated. The most 
widely used oblique rotation is Direct 
Oblimin rotation, which allows the 
axis to deviate from a 90 degree 
angle. 
Label the factors 
Items with high loadings on one and 
only one factor (marker variable) 
will be used to assist with labeling. 
The original items will be reviewed 
to determine what the cluster items 
have in common with each other to 
further refine the label for the factor. 
Internal Consistency Reliability 
Analysis- Cronbach's Alpha. 
 
Three main steps were planned to be performed to complete the Factor Analysis (see 
Table 2). Step one includes the assessment of the suitability of the data for factor analysis (Pallat, 
2013). Two main issues were evaluated to determine if the data were suitable for factor analysis 
(sample size and the strength of the relationship of the items of the modified-FNAST) (Pallat, 
2013). Tabachnick and Fidell (2013) suggest that a sample size greater than 300 is most ideal, 
however, they do acknowledge that a smaller sample size (approximately greater than or equal to 
150) may be sufficient if solutions are noted to have several high loading marker variables above 
.8. Nunnally (1978) suggests that 10 cases for each item to be factored should be adequate. 
Given the M-FNAST is a 21 item instrument a sample size of 210 should be sufficient based on 
this criterion. The Senior IT Analyst from DataLine estimated that there are approximately 209 
infants who met the inclusion criteria without any exclusionary criteria, therefore, we anticipated 
having an adequate sample size to meet the assumptions to accurately perform a factor analysis. 
To assess the strength of the inter-correlations among the items, the correlation matrix 
was inspected for evidence of coefficients greater than .3 (Pallat, 2013). If the inspection 
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revealed that there are few correlations greater than .3, factor analysis may not be appropriate 
(Pallat, 2013). Two statistical tests were also planned to be performed, Bartlett's chi-square test 
(Bartlett, 1954), and Kaiser-Meyer-Olkin Measure of Sampling Adequacy (Kaiser, 1970, 1974). 
The Bartlett’s test of sphericity should be significant with a p value < .05 (Pallat, 2013; Polit, 
2010). The Bartlett’s test of sphericity tests the null hypothesis that the correlations in the matrix 
are zero (that the correlation matrix is an identity matrix) (Polit, 2010). If the null hypothesis 
cannot be rejected than factor analysis is not appropriate (Pallat, 2013; Polit, 2010). The KMO 
index is the ratio of sum of squared correlations to the sum of squared correlations plus the sum 
of squared partial correlations (Polit, 2010). The KMO test is a measure of sampling adequacy 
that compares the magnitude of correlation coefficients to the sizes of partial coefficients. In this 
context, the partial correlation coefficient between two variables is the correlation after 
controlling for the effects of all other variables (Polit, 2010). Values range between 0-1, values 
approaches 1 if the partial correlations are small. Values of .8 or greater are considered good, .7 
fair, and values below .5 are considered unacceptable for factor analysis (Polit, 2010).  
Factor extraction is the second step in the process of factor analysis (Pallat, 2013; Polit, 
2010). Factor extraction involves determining the smallest number of factors that can be used to 
best represent the interrelationships among a set of variables (Pallat, 2013; Polit, 2010). There 
are multiple approaches that can be used to extract the underlying factors or dimensions 
(principal components analysis, and principal axis factoring with or without orthogonal or 
oblique rotation are the most common) (Pallat, 2013; Polit, 2010). The factor solution that best 
addresses two conflicting goals would then be selected. The goal was to obtain the solution with 
as few factors as possible, and which explained as much of the variance in the original data as 
possible (Pallat, 2013; Polit, 2010). Multiple statistical techniques were planned to be used to 
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assist in the decision making process on the final number of factors to retain including: Kaiser’s 
criterion, scree test, and parallel analysis (Pallat, 2013; Polit, 2010). The Kaiser’s criteria or 
eigenvalue rule is the most commonly used technique. According to this rule, only factors with 
an eigenvalue of 1.0 or greater would be retained (Pallat, 2013; Polit, 2010). The eigenvalue of a 
factor represents the amount of the total variance explained by the factor (Pallat, 2013; Polit, 
2010). The Kaiser criteria has been criticized because it may result in the retention of too many 
factors in some situations, therefore, it should not be used as the only criteria (Pallat, 2013). 
Catell’s (1966) scree test involves plotting each of the eigenvalues of the factors and inspecting 
the plot to identify the area at which the shape of the curve abruptly changes direction and 
becomes horizontal (the elbow). Catell (1966) recommends only retaining all the factors above 
the elbow. Parallel analysis as described by Horn (1965) involves comparing the size of the 
eigenvalues with those obtained from a randomly generated data set of the same size. Using this 
approach, only eigenvalues that exceed the corresponding values from the random data set would 
retained in the final solution (Pallat, 2013). This test has been shown to be the most accurate of 
the three (Pallat, 2013). 
Factor rotation and interpretation are the last step in the process of factor analysis (Pallat, 
2013; Polit, 2010). Once the number of factors has been decided, it is necessary to interpret the 
meaning of the factors (Pallat, 2013; Polit, 2010). Rotation (orthogonal and oblique) can be used 
to assist in the interpretation of the factors (Pallat, 2013; Polit, 2010). The process of rotation 
does not alter the underlying solution (Pallat, 2013; Polit, 2010). Rotation presents the patterns of 
loadings in a manner that is easier to interpret by depicting which variables cluster together 
(Pallat, 2013; Polit, 2010). The final interpretation should be based on current theory and past 
research (Pallat, 2013; Polit, 2010). 
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There are two main approaches to rotation: orthogonal which assumes that the factors are 
not correlated, and oblique which assumes the factors are correlated (Pallat, 2013; Polit, 2010). 
Tabachnick and Fidell (2013) suggest, orthogonal rotation generates factor solutions that are 
positioned at a 90 degree angle, easier to interpret, and the researcher must assume that the 
underlying constructs are not correlated (which is usually an incorrect assumption). The most 
widely used orthogonal rotation is Varimax rotation and this can be performed in SPSS (Pallat, 
2013; Polit, 2010). In contrast, oblique rotation allows the axis to deviate from a 90 degree angle, 
and allows for factors to be correlated, however, they are more difficult to interpret (Pallat, 2013; 
Polit, 2010; Tabachnick, & Fidell, 2013). The most commonly used oblique rotation is direct 
oblimin rotation and this is available in SPSS (Pallat, 2013; Polit, 2010). In reality, the two 
approaches often produce similar results especially when the correlations between the items are 
more obvious (Tabachnick, & Fidell, 2013). Because of this phenomena, many researchers 
conduct both orthogonal and oblique rotations and then report the one that is the most clear and 
interpretable (Pallat, 2013; Polit, 2010). According to Thurstone (1947), the goal of rotation is to 
obtain a simple structure. A simple structure is a rotation solution where the variables have a 
high loading on only one factor. Preferably, the factor loadings are as close to 1.00 or -1.00 as 
possible for the variables aligned with a factor, and the loadings are as close to 0.00 as possible 
for variables not aligned with the factor. The factors are then labeled by identifying the marker 
variables and reviewing the original items to determine what the cluster of loadings on a factor 
have in common (Pallat, 2013; Polit, 2010). A Cronbach’s alpha was also to be analyzed to 
determine the internal consistency reliability (Pallat, 2013; Polit, 2010).  
A series of Exploratory Factor Analyses (EFA) were to be performed on the modified-
FNAST scores of infants less than and greater-than 28 days of life admitted to the JHACH 97 
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bed NICU (between January 1, 2010-May 18, 2018). Exploratory factor analysis was planned to 
be used in the analysis of aims 2-4. Exploratory factor analysis of the average modified-FNAST 
scores of infants less than and greater than 28 days of life were to be performed on day 1, 3, 7, 
then weekly, and on the day of discharge to determine the underlying dimensions and explore the 
similarities and differences between the groups. Principle Component Analysis was to be 
conducted to extract variables that accounted for the greatest amount of variance. The serial EFA 
were to be conducted on the two groups of infants (less than and greater than 28 days old) and 
compared in order to determine if the validity and reliability of the inferences of the abstinence 
scores could be extended to infants greater than 28 days of life. In order to fully describe the 
sample population the demographics of the mother and infant dyads were described. The infant’s 
medical record were also reviewed to verify the results of any maternal and infant urine and/or 
meconium drug screen results. The demographic data were analyzed using descriptive statistics 
(frequency and percent) and the results were presented in a table. 
The relationship between the medications used to treat infants for NAS and the 
longitudinal trajectory of the Finnegan scores were described using frequency and percent. 
Descriptive Analyses were used to explore the relationship between the means of the total 
Finnegan scores (on day 1, 3, 7, and then weekly) and the medications used to treat the infants in 
the sample. A repeated measures Mixed Effect Model was used to compare the mean Finnegan 
total scores between the different medication groups after controlling for multiple extraneous 
variables (Tabachnick, & Fidell, 2013). The trajectory of the mean total Finnegan scores and the 
relationship between the medication groups were reported in run charts using excel. 
Summary. In summary, this chapter reviewed the specific study methods. It was 
organized by institutional approvals, funding, design, setting, sample and sampling plan, 
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population, theoretical and operational definition of terms, measures, and study procedures. The 
chapter ended with a detailed description of the data analysis plan according to the specific study 
aims. 
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CHAPTER FOUR: 
RESULTS 
The chapter provides a detailed review of the study results. The chapter begins with a 
description of the demographics of the study sample including critical characteristics on both the 
infants with NAS and their mothers. In addition, the chapter provides a presentation of the study 
results with respect to each the five study aims according to the a priori data analyses plan.  
Aim #1 
To determine which of the 21 items in the modified-FNAST are most predictive of the 
need for pharmacological treatment in infants greater than 28 days of life diagnosed with NAS, 
Logistic Regression was used (Tabachnick, & Fidell, 2013). 
Aim #2  
To explore the interrelationships among the 21 items of the modified-FNAST to 
determine the underlying structure in infants less than 28 days of life diagnosed with NAS 
experiencing acute drug withdrawal. Exploratory Factor Analysis was used (Tabachnick, & 
Fidell, 2013). 
Aim #3  
To explore the interrelationships among the 21 items of the modified-FNAST to 
determine the underlying structure in infants greater than 28 days of life diagnosed with NAS 
experiencing acute drug withdrawal. Exploratory Factor Analysis was used (Tabachnick, & 
Fidell, 2013). 
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Aim #4 
Comparison was made between the underlying structures of the interrelationships of the 
items of the modified-FNAST as determined by the EFA in infants less than and greater than 28 
days of life diagnosed with NAS experiencing acute drug withdrawal.  
AIM #5  
The relationship between the medications used to treat infants for NAS and the 
longitudinal trajectory of the total Finnegan scores was described. Descriptive Analyses was 
used to explore the relationship between the means of the total Finnegan scores (on day 1, 3, 7, 
and then weekly) and two of the medications (clonidine and phenobarbital) used to treat the 
infants in the sample. A repeated measures Mixed Effect Model was used to compare the mean 
total Finnegan scores between the different medication groups (infants treated and non-treated 
with clonidine and phenobarbital) (Tabachnick, & Fidell, 2013). The infants treated with 
clonidine and phenobarbital were selected because there were ample infants in both the treated 
and non-treated groups for comparison. The trajectory of the mean total Finnegan scores and the 
relationship between the medication groups (infants treated and non-treated with clonidine and 
phenobarbital) were reported in run charts using excel. 
Demographics of the Sample 
The partial medical records of 208 infants diagnosed with NAS who had documented 
modified-FNAST scores, hospitalized in the NICU at JHACH between January 1, 2010 and May 
18, 2018, and met the inclusion criteria without any evidence of exclusionary criteria comprised 
the convenience sample. To meet the inclusion criteria, the infants must have been born to an 
opiate-dependent mother, admitted to the NICU with a primary diagnosis of NAS (between the 
date of birth and day 3 of life), and required pharmacological treatment. Infants diagnosed with 
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NAS who had life threatening conditions in which NAS was a secondary diagnosis, or were 
discharged from other inpatient units, or premature (less than 37 weeks) were excluded from the 
study.  
Infant Demographics. The de-identified demographic data on the infants in the study 
sample extracted from the electronic medical record (EMR) are described below in Table 3 
(including birth weight, gestational age, gender, day of life admitted to the NICU, summary of 
the drugs used to treat the infants drug withdrawal, and the results of the urine and meconium 
drug screen results when performed). The infants in the sample were all born at outlying 
hospitals and transported to the study site hospital (a 97 bed level 4 NICU located within a free 
standing children’s hospital in south west, Florida). The infants were admitted to the NICU 
between days 1-3, with a median admission date of 1.12 days. The gestational ages of the infants 
ranged from 37 to 42 weeks with a mean gestational age of 38.91 weeks and a standard deviation 
(SD) of 1.133 weeks. The infants birth weights ranged from 1.99 – 5.09 kg, SD = 0.479 kg. 
Methadone (n = 138, 66.7%) was the most common drug reported positive on the infant urine 
drug screen followed by morphine (n = 59, 28.5%) (likely due to the timing of the drug screen 
after the infant was already started on treatment for NAS), benzodiazepines (n = 23, 11.1%), 
oxycodone (n = 12, 5.8%), and other drugs (n = 97, 46.9%) (including opiates, THC, 
amphetamine, temazepam, oxazepam, and alprazolam). Only 9 (4.3%) infants did not have a 
urine drug screen result documented in the EMR. In contrast, only two (1%) of the infants in the 
sample had a meconium drug screen result documented and both were positive for methadone. 
The four most common drugs used to treat the infants for NAS were consistent with the JHACH 
weaning protocol and included, morphine (n = 205, 99.0%), phenobarbital (n =137, 66.2%), 
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clonidine (n = 52, 25.1%), and buprenorphine (n = 4, 1.9%). No infants were treated with 
methadone. 
Table 3. Demographics: Infants 
Characteristic  (n=207) 
Birth weight; range, mean, (SD) 1.99-5.09 kg, 3.067 kg (0.479) 
Gestational age; range, mean (SD) 37-42 weeks, 38.91 weeks (1.133) 
Gender n (%):  
     Male 100 (48.3%) 
     Female 107 (51.7%) 
Day of life admitted to the NICU range in days, 
mean in days 
1-3 (1.12) 
Drugs used to treat NAS n (%)  
     Morphine 205 (99.0%) 
     Buprenorphine 4 (1.9%) 
     Clonidine 52 (25.1%) 
     Phenobarbital 137 (66.2%) 
     Methadone 0 (0%) 
Urine drug screen result  
     None 19 (9.2%) 
     Methadone 138 (66.7%) 
     Morphine 59 (28.5%) 
     Marijuana  3 (1.4%) 
     Cocaine 11(5.3%) 
     Oxycodone 12 (5.8%) 
     Hydromorphone 5 (2.4%) 
     Methamphetamine 7 (3.4%) 
     Benzodiazepine 23 (11.1%) 
     Barbiturates 2 (1.0%) 
     Other (opiates, thc, amphetamine, temazepam, oxazepam,  
       and alprazolam) 
97 (46.9%) 
     Unknown/Not Reported 9 (4.3%) 
Meconium drug screen  
     Methadone 2 (1%) 
     Unknown/Not Reported 204 (98.6%) 
Note: Exclude listwise was executed in SPSS to run the analyses. 
 
Maternal Demographics. The mothers were inpatients of the referral hospital, and 
consequently were not hospitalized at the same institution as the infant. The de-identified 
demographic data on the mothers were obtained from the documentation in the medical NICU 
admission, discharge, or social work notes, sections of infant’s EMR are described in Table 4 
(including age, race, ethnicity, highest education level achieved, significant mental health and 
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trauma history, significant drug history, and urine drug screen results when performed). Most of 
the mothers (n = 182) self-reported that they were in a drug treatment program and were treated 
with opioid replacement therapy over the course of the pregnancy including, 174 (84.1%) treated 
with methadone, and 8 (3.9%) treated with buprenorphine respectively. The maternal urine drug 
screen results revealed 92 (44.4%) of the mothers were positive for methadone. Other drugs 
reported as positive on the urine drug screens of the mothers in the sample included, 13 (6.3%) 
marijuana, 19 ( 9.2%) oxycodone, 35 (16.9 %) benzodiazepines, and 35 positive for other illicit 
drugs including (opioids, amphetamines, clonazepam, dilaudid, and THC), No urine drug screen 
results were reported for 37.2% of the mothers (n =77). Smoking was self-reported by (n = 157, 
75.8%) of the mothers. Of the mothers who reported smoking, 17 (8.2%) reported smoking 1-5 
cigarettes per day, 64 (30.9%) reported smoking 6-10 cigarettes per day, 8 (3.9%) reported 
smoking 11-15 cigarettes per day, 30 (14.5%) reported smoking 16-20 cigarettes per day, and 3 
(1.4%) reported smoking greater than 2 packs per day. 
The ages of the mothers ranged from 18-47 years. Several maternal characteristics were 
not documented in the EMR for most of women including maternal race (unknown n = 202, 
97.6%), ethnicity (unknown n = 202, 97.6%), and highest education level (unknown n = 206, 
100%) respectively. The mothers self-reported multiple common mental health conditions 
including anxiety (n = 58, 28%), and depression (n = 65, 31.4%). The mental health history for 
83 (40.1%) of the mothers was unknown. Other mental health or trauma related histories were 
reported in the mothers (n = 89, 43%)  including, post-traumatic stress syndrome, rape, domestic 
violence, motor vehicle accidents (MVA), death of a child, incarceration, HIV, suicide attempt, 
panic disorder, baker acted, and bi polar disorder.  
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Table 4. Demographics: Mothers 
Characteristic  
Age in years, range, mean ) 18-47, 28.45 
Race n (%):  
     American Indian or Alaska Native  
     Asian 1 (0.5%) 
     Black or African American  
     Native Hawaiian or Other Pacific Islander  
     White 3 (1.4%) 
     Other  
     Unknown/Not Reported 202 (97.6%) 
Ethnicity n (%):  
     Hispanic or Latino  
    Not Hispanic or Latino 4 (1.9%) 
     Unknown/Not Reported 202 (97.6%) 
Highest level of education achieved, mean (SD)  
     Unknown/Not Reported 206 (100%) 
Mental health, trauma history, mean (SD)  
     None 1(0.5%) 
     Anxiety 58 (28%) 
     Depression 65 (31.4%) 
     Post-Traumatic Stress Syndrome 5 (2.4%) 
     History of Physical Abuse 1 (0.5) 
     Other 89 (43%), (Included Reports of: MVA, Domestic 
Violence, Incarceration, Rape, HIV, Suicide Attempt, 
Panic Disorder, Baker Acted, and Bipolar Disorder) 
     Unknown/Not Reported 83 (40.1%) 
Maternal self-reported drug history  
     None 3 (1.4% 
     Methadone 174 (84.1%) 
     Morphine 5 (2.4 %) 
     Buprenorphine 8 (3.9%) 
     Heroin 4 (1.9%) 
     Xanax 22 (10.6%) 
     Marijuana  24 (11.6%) 
     Cocaine 18 (8.7%) 
     Roxycodone 13 (6.3%) 
     Oxycodone 37 (17.9%) 
     Hydrocodone 4 (1.9%) 
     Tylenol #3 1 (0.5%) 
     Valium 7 (3.4%) 
     Hydromorphone 11 (5.3%) 
     Zoloft 4 (1.9%) 
     Tramadol 2 (1.1%) 
     Demerol 2 (1%) 
     Alcohol 20 (9.7%) 
     Benzodiazepine 7 (3.4%) 
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Table 4. Demographics: Mothers Continued  
 
    Other 63 (30.4%)  
(Included Reports of: illicit opioids, recreational drug 
use, Abilify, Seroquel, Flexeril, Lamictal, Tegretal, 
Chewing Tobacco, Citalopram, Amitriptyline, 
Clonazepam, Crack, Dilaudid, Cymbalta, Floracet, 
Lexapro, THC, Lortab, Nicoderm Patch, Percocet, 
Prozac, Soma, Temazepam, Tylenol, Vicoden, 
Wellbutrin, Zofran, Phenergan, and Zolpidem) 
     Unknown/Not Reported 2 (1%) 
Maternal urine drug screen result  
     None 9 (4.3%) 
     Methadone 92 (44.4%) 
     Xanax 3 (1.4%) 
     Marijuana  13 (6.3%) 
     Cocaine 17 (8.2%) 
     Roxycodone 1 (0.5%) 
     Oxycodone 19 (9.2%) 
     Valium 2 (1.0%) 
     Hydromorphone 1 (0.5%) 
     MDMA (ecstasy) 2 (1.0%) 
     Benzodiazepine 35 (16.9%) 
     Barbiturates 3 (1.4%) 
     Other 35 (16.9%) 
(Included Reports of: Opioids, Amphetamine, 
Clonazepam, Dilaudid, and THC) 
     Unknown/Not Reported 77 (37.2%) 
Smoking History  
Smoker 157 (75.8%) 
Non Smoker 35 (16.9%) 
1-5 Cigarettes per day 17 (8.2%) 
6-10 Cigarettes per day 64 (30.9%) 
11-15 Cigarettes per day 8 (3.9%) 
16-20 Cigarettes per day 30 (14.5%) 
21-30 Cigarettes per day 0 (0%) 
31-40 Cigarettes per day 2 (1.0%) 
Greater than 40 Cigarettes per day 3 (1.4%) 
Unknown/Not Reported 46 (22.2%) 
Note: Exclude listwise was executed in SPSS to run the analyses. 
 
 
Results of Aim 1 
To determine which of the 21 items on the modified-FNAST were most predictive of the 
need for pharmacological treatment in infants less than and greater than 28 days of life diagnosed 
with NAS, regression analysis was planned using SPSS version 24. Logistic regression 
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procedure was attempted with all 21 predictors or independent variables (IV) (which included all 
21 item scores on the modified-FNAST entered at the same time) regressed on the dichotomized 
dependent variable (DV), need for pharmacological treatment (morphine yes/no, buprenorphine 
yes/no, clonidine yes/no, phenobarbital yes/no).   
Preliminary analyses were performed on the 21-items of the modified-FNAST specific 
variables necessary to perform the exploratory factor analyses (including graphing the variables 
using histograms and scatterplots) and it was determined there were significant violations to the 
assumptions of normality, and linearity. Statistical tests to determine normality (including 
Kolmogorov-Smirnov and Shapiro-Wilk) were performed on each of the 21-item modified-
FNAST variables and both tests were noted to be statistically significant (p < 0.0001) for each of 
the variables on day of life (dol) one suggesting that the variables were not normally distributed 
(see Table 5).  
Table 5. Tests of Normality for Each of the 21-Item Modified-FNAST Variables (DOL 1) 
DOL 1 Kolmogorov-Smirnov Shapiro-Wilk 
Modified-FNAST 
Item 
Statistic df Sig. Statistic df Sig. 
Bowel Movement .519 207 .000 .214 207 .000 
Convulsion .523 207 .000 .043 207 .000 
Crying .432 207 .000 .547 207 .000 
Excoriation .532 207 .000 .111 207 .000 
Feeding .435 207 .000 .565 207 .000 
Moro .450 207 .000 .474 207 .000 
Mottling .482 207 .000 .435 207 .000 
Muscle Tone .412 207 .000 .625 207 .000 
Nasal Flaring .535 207 .000 .136 207 .000 
Nasal Stuffiness .510 207 .000 .269 207 .000 
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Table 5. Tests of Normality for Each of the 21-Item Modified-FNAST Variables (DOL 
1)Continued 
Respirations .486 207 .000 .355 207 .000 
Sleep .398 207 .000 .580 207 .000 
Sneeze .485 207 .000 .384 207 .000 
Suck .468 207 .000 .450 207 .000 
Sweat .515 207 .000 .234 207 .000 
Temperature .481 207 .000 .398 207 .000 
Tremors Disturbed .390 207 .000 .682 207 .000 
 Tremors 
Undisturbed 
.451 207 .000 .480 207 .000 
Vomiting .535 207 .000 .168 207 .000 
Yawning .523 207 .000 .043 207 .000 
Note: DOL= day of life; Sig = .000 = p < .0001; and df = degrees of freedom. 
This same pattern of non-normality was also observed on dol 3, 7, and then weekly until 
discharge. In addition, the correlation matrix generated from the data was examined and it 
revealed violations to the assumption of multicollinearity, and singularity. The correlation matrix 
revealed many correlations between the different variables below 0.3, and multiple correlations 
greater than 0.7, with some as high as 0.995 (with exclude listwise executed) and as high as 1 
(pairwise executed). As a result, the relationships between the 21 items of the modified-FNAST, 
and the need for pharmacological treatment could not be further analyzed.  
Results of Aims 2 and 3 
To explore the interrelationships among the 21 items of the modified-FNAST to 
determine the underlying structure in infants less than and greater than 28 days of life, diagnosed 
with NAS and experiencing acute drug withdrawal, multiple exploratory factor analyses (EFA) 
were attempted using SPSS version 24. Multiple EFAs were attempted to examine the data sets 
67 
 
(on day of life 1, 3, 7, and weekly) from a sample of infants who were admitted to the JHACH 
NICU between January 1, 2010 to May 18, 2018 with a diagnosis of NAS requiring 
pharmacological treatment, and were scored on the 21 items from the modified- FNAST to 
assess the severity of their drug withdrawal. The 21 items included the following signs of acute 
drug withdrawal (Finnegan & Kaltenbach, 1992). 
1. Cry: Excessive high pitched cry, Continuous high pitched cry 
2. Sleep: Sleeps < 1 hour after feeding, Sleeps < 2 hours after feeding, Sleeps < 3 hours 
after feeding 
3. Moro reflex: Hyperactive Moro reflex, Markedly hyperactive Moro reflex 
4. Tremors: Mild tremors when disturbed, Moderate-severe tremors when disturbed, Mild 
tremors when undisturbed. Moderate-severe tremors when undisturbed 
5. Increased muscle tone 
6. Excoriation (chin, knees, elbow, toes, nose) 
7. Myoclonic jerks (twitching/jerking of limbs) 
8. Generalized convulsions 
9. Sweating 
10. Hyperthermia: Hyperthermia (37.2-38.3 C), Hyperthermia (>38.4C) 
11. Frequent yawning (>3-4 times per scoring interval) 
12. Mottling 
13. Nasal stuffiness 
14. Sneezing (>3-4 times per scoring interval) 
15. Nasal flaring 
16. Respiratory: Respiratory rate ((>60/min), Respiratory rate (>60/min with retractions) 
17. Excessive sucking 
18. Poor feeding (infrequent/uncoordinated suck) 
19. Regurgitation: Regurgitation (>2 times during /post feeding); Projectile vomiting 
20. Loose stools (curds/seedy appearance) 
21. Watery stools (water ring on diaper around stool) 
 
The analysis plan was to include a comparison of the Factor Solutions at multiple critical 
intervals according to the study aims. To determine how many components (factors) to extract 
the SPSS output from the 207 infants was to be examined on day 1, 3, 7, and weekly until 
discharge, Principal Component Analysis (PCA) with and without Oblimin rotation analyses was 
to be performed. Factor Solutions were then to be evaluated for eigenvalues greater than 1, the 
largest total variance explained by the solution, and the change in the shape (or elbow) of the 
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Screeplot. In addition, Parallel Analysis was to be performed as the third method to determine 
the number of factors to retain. Monte Carlo PCA for Parallel Analysis is performed (by entering 
the number of variables (21), number of participants in the sample (207), and the number of 
replications performed (100 specified). The eigenvalues obtained from SPSS analysis were then 
to be compared to the randomly generated samples from the Monte Carlo PCA Parallel Analysis. 
Only eigenvalues greater than the criterion values generated from the Parallel Analysis were to 
be retained as factors. The factor solution which explained the greatest amount of the variance 
with the least number of factors were to be retained. The decisions regarding how many factors 
to extract and the most appropriate factor extraction and rotation method to use to generate the 
final solution was to be determined by running multiple approaches separately and then 
comparing them. The goal was to obtain a simple solution to provide clear results by maximizing 
the separation between factors with high loadings and factors with low loadings. The factor 
loading would be inspected to determine the marker variables indicated by variables with high 
factor loadings (.8 or greater) on ideally only one factor and close to zero on the rest would be 
used to label the factor. The factors would be labeled by comparing the item stems of the marker 
variables to determine what the factor loadings with similar high loadings have in common. The 
factor solution which is noted to explain the greatest amount of the variance with the least 
number of factors, and the purest interpretation would be retained.  
Determination of Suitability of the Data Sets for Factor Analysis. The specific 
variables related to the 21 items of modified-FNAST from the data set extracted from the 
DataLine warehouse were examined and found to have several limitations. Two of the modified-
FNAST score items (myoclonic jerks and convulsions) were coded as dichotomized variables 
(with values of 0 or 1) indicating the absence or presence of the symptom respectively. In order 
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for SPSS to accurately execute the analyses these items needed to be entered as averaged score 
values and coded as scale variables which was not done. All other modified-FNAST score items 
were coded as scale variables, and reflected the mean score for that item over the 24 period. 
Infants are assessed and scored for severity of drug withdrawal using the 21 item modified-
FNAST every 3-4 hours after feeding. Further inspection of the data also revealed that the last 2 
items on the modified-FNAST (loose and watery stools) were coded as one variable bowel 
movement (BM) according to how the instrument appeared on the drop down screen in the EMR 
when the nurses chart. The specific variables of the modified-FNAST data sets on day of life 1, 
3, 7, and weekly were determined to be unsuitable for factor analyses due violations to the 
assumptions of normality and linearity as described above. Further inspection of the Correlation 
Matrices produced from the specific data sets revealed most correlation coefficients below 0.3, 
and multiple correlation coefficients greater than 0.7 and as high as 0.995 between multiple 
independent variables in addition to the variable compared to itself (expected correlations of 1 
which normally occur along the diagonal of the matrix). The sample size was adequate given that 
there was approximately a 1 to 10 ratio of cases for each item to be factor analyzed (21 items are 
included in the modified-FNAST X 10 cases per item = a sample size estimate of 210). The 
actual sample size included (n = 207, with n = 196 remaining in the sample for analysis even 
when listwise exclusion was executed in SPSS to ensure the stability of the Correlation Matrix). 
However, no further analysis could be performed due to the unreliable nature of correlation 
matrix which was generated from the specific required variables in the data set. The correlation 
matrix must be reliable and stable as it serves as the basis for all subsequent sub analyses 
necessary to perform an accurate factor analysis (including factor extraction, rotation, 
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interpretation of factor loadings, and reliability testing). Given that the correlational matrix was 
not reliable, no further analysis was performed. 
Results of Aim 4 
It was not possible to make any comparisons of the underlying structures of the 
interrelationships of the items of the modified-FNAST as determined by a series of exploratory 
factor analyses (EFA) in infants less than and greater than 28 days of life diagnosed with NAS 
experiencing acute drug withdrawal because the preliminary tests could not be reliably 
performed.  
Results of Aim 5 
The descriptive statistics for the total modified-FNAST scores on day 1, 3, 7, and weekly 
until discharge for the infants with NAS are reported in Table 6. The total modified-FNAST 
scores ranged from 0-21 on day 1 of life with a mean of 8.68 and a SD (4.127), and then 
gradually decreased over the length of the hospitalization until discharge.  
Table 6. Summary of the Descriptive Statistics for the Total Finnegan Scores by DOL (n = 207) 
  Descriptive Statistics 
Total Finnegan Score 
by DOL,  
n  Range Minimum Maximum Mean SD 
DOL 1 146  21 0 21 8.68 4.127 
DOL 3 202  17 0 17 6.39 3.179 
DOL 7 203  12 0 12 4.73 2.280 
DOL 14 204  14 0 14 4.10 2.132 
DOL 21 205  11 0 11 3.86 2.122 
DOL 28 206  10 0 10 3.82 2.061 
DOL 35 141  12 0 12 3.68 2.227 
DOL 42 91  11 0 11 3.44 2.414 
DOL 49 50  8 0 8 3.40 1.829 
DOL 56 28  7 0 7 2.82 1.887 
DOL 63 16  7 0 7 2.44 2.279 
DOL 70 4  6 0 6 4.50 3.000 
DOL 77 3  3 2 5 3.00 1.732 
DOL 84 2  4 0 4 2.00 2.828 
DOL D/C 198  10 0 10 2.38 1.792 
Note: DOL=day of life, discharge= D/C 
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All medications used to treat the infants for NAS and are described in Table 7. Most of 
the infants received morphine as monotherapy or in combination with phenobarbital or clonidine 
consistent with the established JHACH NAS weaning protocol. The four most common 
medications used to treat the infants for NAS in relative rack order included, morphine (99.0%), 
phenobarbital (66.2%), clonidine (25.1%), and buprenorphine (1.9%). 
Table 7. Summary of the Descriptive Statistics of Medications Used to Treat NAS (n =207) 
 Descriptive Statistics 
Medications  n Treated Percent n Not Treated Percent 
Morphine  205 99.0% 2 1.0% 
Buprenorphine  4 1.9% 203 98.1% 
Clonidine  52 25.1% 155 74.9% 
Phenobarbital  137 66.2% 70 33.8% 
 
The minimum and maximum, and duration of treatment for each of the drugs are 
described in Table 8.  
Table 8.  
Summary of the Minimum-Maximum Dose and Treatment Length for the Medications Used to 
Treat NAS 
 Descriptive Statistics n = 207 
Medications  Min 
Dose 
Max 
Dose 
Min 
Duration of 
Inpatient 
Treatment 
Days  
Max Duration 
of Inpatient 
Treatment 
Days 
Median 
Duration of 
Inpatient 
Treatment Days 
SD Duration 
of Inpatient 
Treatment 
Days 
Morphine 
(mg/kg/day) 
 0.33 2.170 14.00 81.00 32.00 11.69 
Buprenorphine 
(mcg/kg/day) 
 7.00 61.30 4.00 30.00 8.00 11.82 
Clonidine 
(mcg/kg/day) 
 3.97 28.93 16.00 87.00 32.00 14.77 
Phenobarbital 
(mg/kg/day) 
 3.00 16.00 2.00 84.00 21.50 17.67 
Note: Min = minimum; Max = maximum; SD = standard deviation; Exclude listwise was entered in SPSS to run the 
analyses. 
 
Trajectory of Mean M-FNAST Scores and Medications Used to Treat NAS. The 
relationship between the medications used to treat the infants for NAS and the longitudinal 
trajectory of the Finnegan scores were further explored. Descriptive analyses were used to 
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describe the relationship between the means of the total modified-FNAST scores (on day 1, 3, 7, 
and then weekly) for two of the medications (clonidine and phenobarbital) used to treat the 
infants for NAS. The longitudinal trajectory of the mean total Finnegan scores on day of life 1, 3, 
7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, & 84, and the relationship between the treated and non-
treated medication groups (including clonidine and phenobarbital) are reported in the run chart 
below (see Figure 4). These specific variable data were determined to be appropriate for analyses 
because they were collected as ordinal level, total modified-FNAST scores, and coded as scale 
variables which were normally distributed. 
 
Figure 4. Trajectory of Mean M-FNAST Scores and Medications Used to Treat NAS 
Mixed Effects Models. We performed a mixed effects models for the repeated measures 
of the TOTAL Finnegan score.  SAS PROC MIXED was used with the total Finnegan score as 
the Dependent Variable and the two medications (clonidine and phenobarbital) as the primary 
Independent Variables controlling for infant birthweight, infant gender, estimated number of 
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cigarettes during pregnancy, infant gestational age (see Tables 9, 10, 11, 12, 13, 14, 15, 16, 17, 
and 18 below which detail the mixed procedure performed using the SAS System). 
Table 9. Summary of the Mixed Effects Model Information 
Model Information 
Data Set Work, Transposed 
Dependent Variable Total Finnegan Scores 
Covariance Structures Autoregressive, Variance Components 
Subject Effects ID, ID 
Estimate Method REML 
Residual Variance Method Parameter 
Fixed Effects SE Method Model-Based 
Degrees of Freedom Method Containment 
 
 
Table 10. Summary of the Mixed Effects Model Class Level Information 
Class Level Information 
Class Levels Values 
ID 124 2,3,4,6,7,8,9,11,14,1516,18,19,21,22,25,26,27,29,31,32,33,36,37,38,39,50,51,52,55, 
56,58,59,60,62,63,64,66,69,71,72,73,74,76,77,79,80,82,85,88,89,90,92,93,95,96,97, 
99,101,104,105,106,108,109, 110, 111, 113, 118, 120, 121, 122, 123, 126, 127, 128, 
129, 131, 135, 137, 138, 139, 140, 141, 144, 145, 146, 147, 148, 149, 150, 152, 154, 
155, 156, 157, 158, 161, 162, 164, 165, 167, 172, 173, 174, 175, 177, 180, 181, 185, 
186, 188, 189, 190, 191, 193, 195, 196, 198, 200, 201, 202, 203, 204, 207 
Gender_infant 2 0,1 
tx_inf_nas_4 2 0,1 
tx_inf_nas_5 2 0,1 
Note: Tx  =  treat; inf  =  infant; and ID = participant unique identifier number.. 
 
Table 11. Summary of the Mixed Effects Model Dimensions 
Dimensions 
Covariance Parameters 3 
Columns in X 15 
Columns in Z per Subject 1 
Subjects 124 
Maximum Observations per Subject 13 
 
Table 12. Summary of the Number of Observations for the Mixed Effects Model 
Number of Observations 
Number of Observations Read 2898 
Number of Observations Used 907 
Number of Observations Not Used 1991 
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Table 13. Mixed Effects Model Iteration History 
Iteration History 
Iteration Evaluations -2 Res Log Like Criterion 
0 1 4543.62193798  
1 2 4543.62253444 0.00000494 
2 1 4543.62193801 0.00000000 
Note: Convergence criteria met but final hessian is not positive definite. 
 
 
 
Table 14. Mixed Effects Model Covariance Parameter Estimates 
Covariance Parameter Estimates 
Covariance Parameter Subject Estimate 
Variance ID 0 
AR(1) ID 0 
Residual ID 8.6427 
Note: AR  = Auto regressive 
 
 
Table 15. Summary of Fit Statistics for Mixed Effects Model 
Fit Statistics 
-2 Res Log Likelihood 4543.6 
AIC (Smaller is Better) 4547.6 
AICC (Smaller is Better) 4547.6 
BIC (Smaller is Better) 4553.3 
Note: AIC = Akaike Information Criterion; AICc = Corrected Akaike Information Criterion; and BIC = Bayesian 
Information Criterion. 
 
 
Table 16. Null Model Likelihood Ratio Test for Mixed Effects Model  
Null Model Likelihood Ratio Test 
DF Chi-Square Pr >  ChiSq 
1 0.00 1 
   
   
Note: ChiSq = Chi-Square, and DF = degrees of freedom. 
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Table 17. Summary of the Solution for the Fixed Effects Model 
Solution for Fixed Effects 
Effect Infant 
Gender 
Tx 
Clonidine 
Tx 
Phenobarbital 
Estimate SE DF t-value Pr > |t| 
Intercept    6.5199 3.6151 117 1.80 0.0739 
Infant Gender 0   -0.09947 0.2038 781 -0.49 0.6257 
Infant Gender 1   0 . . . . 
Birthweight    0.01880 0.2397 781 0.08 0.9375 
Gestational Age    -0.01919 0.09777 781 -0.20 0.8444 
Estimated number of 
cigarettes smoked per 
day during pregnancy 
   0.02730 0.07907 781 0.35 0.7300 
DAY    -0.01991 0.004721 781 -4.22 <.0001 
Tx_inf_nas_4 
(Clonidne) 
 0    -0.8441 0.2847 781 -2.97 0.0031 
Tx_inf_nas_4 
(Clonidine) 
 1  0 . . . . 
Tx_inf_nas_5 
(Phenobarbital) 
  0 0.1505 0.3712 781 0.41 0.6852 
Tx_inf_nas_5 
(Phenobarbital) 
  1 0 . . . . 
Tx_inf_na*tx_inf_nas  0 0 -0.2174 0.4663 781 -0.47 0.6412 
Tx_inf_na*tx_inf_nas  0 1 0 . . . . 
Tx_inf_na*tx_inf_nas  1 0 0 . . . . 
Tx_inf_na*tx_inf_nas  1 1 0 . . . . 
Note: Tx  =  treat; inf  =  infant, DF =  degrees of freedom, SE =  standard error. 
 
Table 18. Summary of Type 3 Tests of Fixed Effects 
Type 3 Tests of Fixed Effects 
Effect Num DF Den DF F-value Pr > F 
Infant Gender 1 781 0.24 0.6257 
Birthweight 1 781 0.01 0.9375 
Gestational Age 1 781 0.04 0.8444 
Estimated number of cigarettes 
smoked per day during pregnancy 
1 781 0.12 0.7300 
DAY 1 781 17.78 <.0001 
Tx_inf_nas_4 (Clonidne) 1 781 16.60 <.0001 
Tx_inf_nas_5 (Phenobarbital) 1 781 0.03 0.8579 
Tx_inf_na*tx_inf_nas 1 781 0.22 0.6412 
Tx  =  treat; inf  =  infant, Num =  Numinator, Den = Denominator, DF = degrees of freedom. 
Both the mean effects and the interaction of the two medications were tested. The effect of TIME 
was also tested by using the DAY variable which is the day a specific total Finnegan score was 
measured.  The Akaike Information Model (AIC) criteria was used for model selection.  The 
Auto Regression Model (AR) (1) correlation structure was used to model the serial correlations 
among the repeated measures of the total Finnegan scores. The Mixed Effects Model Analysis 
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revealed that there was an overall decline of total Finnegan scores over time (p < 0.0001). The 
mean total Finnegan scores showed a statistically significant difference in the groups treated and 
not with clonidine (tx_inf_nas_4) (p = 0.0031). The group treated with clonidine had higher 
mean Finnegan scores.  The infants treated and not treated with phenobarbital (tx_inf_nas_5) did 
not show a significant association with the total Finnegan scores (p = 0.6852). All other control 
variables failed to show significant associations with the repeated measures of total Finnegan 
scores including gender (p = 0.6257), infant birth weight (p = 0.9375), gestational age (p = 
0.8444) and estimated number of cigarettes smoked by the mother during the pregnancy (p = 
0.7300).  The interaction between the two medications (clonidine and phenobarbital) were not 
statistically significant either (p = 0.6412). 
Summary 
In summary, the chapter provided a detailed review of the study results. The chapter 
began with a description of the demographics of the study sample including critical 
characteristics on both the mother and the infants with NAS. In addition, the chapter provided a 
presentation of the study results with respect to each the five study aims according to the a priori 
data analyses plan.  
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CHAPTER FIVE: 
DISCUSSION 
 
The final chapter of this dissertation begins with an overview of the study findings. 
Exploration of how the study findings compare and contrast to the existing published literature 
will then be discussed. In addition, the limitations of the study will be examined. Finally, the 
implications for current practice and future research will be considered.  
Discussion of Study Findings 
It was not possible to determine which of the 21 items on the modified-FNAST were 
most predictive of the need for pharmacological treatment in infants less than and greater than 28 
days of life, diagnosed with NAS, using logistic regression analysis. It was also not possible to 
explore the interrelationships among the 21 items of the modified-FNAST to determine the 
underlying structure in infants with NAS less than and greater than 28 days of life experiencing 
acute drug withdrawal using multiple exploratory factor analyses. As explained previously, the 
specific variables in the data set related to the 21 items of modified-FNAST were examined and 
found to have several limitations. Two of the modified-FNAST score items (myoclonic jerks and 
convulsions) were found to have been coded as dichotomized variables (with values of 0 or 1) 
indicating the absence or presence of the symptom respectively. In order for SPSS to accurately 
execute the analyses these items needed to have been obtained as raw score values and coded as 
scale variables and this was not done. All other modified-FNAST score items were coded 
correctly as scale variables, and reflected the mean score for that item over the 24 period 
(average of all scores documented in the EMR for the 24 hour period for that symptom). Infants 
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are assessed and scored for severity of drug withdrawal using the 21 item modified-FNAST 
every 3-4 hours after feeding. Further inspection of the data also revealed that the last 2 items on 
the modified-FNAST (loose and watery stools) were coded as one variable bowel movement 
(BM) according to how the instrument appears on the drop down screen in the EMR when the 
nurses document. The specific variables of the modified-FNAST data sets on day of life 1, 3, 7, 
and weekly were determined to be unsuitable for factor analyses. The data were not all ordinal 
level data approximating interval level data, and therefore were not normally distributed. This 
was evident from inspecting the Correlation Matrices which were produced from the data sets 
that revealed correlation coefficients as high as 0.995 between multiple independent variables in 
addition to the variable compared to itself (suggesting evidence of multicollinarity). The sample 
size was adequate given that there was approximately a 1 to 10 ratio of cases for each item to be 
factor analyzed (21 items are included in the modified-FNAST X 10 cases per item = a sample 
size estimate of 210). The actual sample size included 208 infants and 196 remained in the 
sample for analysis even after listwise exclusion was executed in SPSS (to ensure the stability of 
the Correlation Matrix). However, no further analysis could be performed due to the unreliable 
nature of correlation matrix which was generated from the specific required variables in the data 
set. The correlation matrix must be reliable and stable as it serves as the basis for all subsequent 
sub analyses necessary to perform an accurate factor analysis (including factor extraction, 
rotation, interpretation of factor loadings, and reliability testing). Given that the correlational 
matrix was not reliable, no further analysis was performed. 
The relationship between the means of the total Finnegan scores (on day 1, 3, 7, and then 
weekly until discharge) and the medications used to treat the infants in the sample were explored 
using descriptive statistics. The results of the study revealed that the total modified-FNAST 
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scores ranged from 0-21 on day 1 of life with a mean of 8.68 and a SD (4.127), and then 
gradually decreased over the length of the hospitalization until discharge. Four medications were 
used to treat the infants for NAS. The medication used to treat the infants for NAS included 
morphine (99%), phenobarbital (66.2%), clonidine (25.1%), and buprenorphine (1.9%). The 
minimum to maximum dosage and minimum and maximum duration of inpatient treatment days 
for each of the medications were examined and revealed, morphine (dosage range, 0.33-2.170 
mg/kg/day and duration of 14-81 days), buprenorphine (dosage range 7.00-61.30 mcg/kg/day 
and duration of 4.00-30.00 days), clonidine (dosage range 3.97-28.93 mcg/kg/day and duration 
of 16.00-87.00 days), and phenobarbital (dosage range 3.00-16 mg/kg/day and duration of 2.00-
84.00 days). Most of the infants received morphine alone or in combination with phenobarbital 
or clonidine consistent with the established evidence-based JHACH NAS weaning protocol. The 
medications used to treat the infants with NAS in this study sample were consistent with the 
2012 AAP guidelines which recommend that pharmacological management of infants with NAS 
due to prenatal exposure to an opioid include treatment with an opiate derivative (Hudak & Tan, 
2012). According to the 2012 AAP recommendations, morphine and methadone are considered 
first line therapy, while phenobarbital and clonidine are considered adjunctive therapies for NAS 
infants with persisting signs despite treatment with an opiate derivative (Hudak & Tan, 2012).  
The trajectory of the modified-FNAST scores and the medications used to treat the 
infants were consistent with the JHACH NAS established weaning protocol. According to the 
established JHACH protocol for weaning NAS infants greater than 35 weeks gestation, all infant 
admitted to the NICU with a diagnosis of NAS are treated with non-pharmacological 
interventions first. Infants are started on pharmacological treatment with oral morphine (0.04 
mg/kg/dose every 3 hours with feedings) if their modified-FNAST scores are greater than 8 
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times two consecutive scores or greater than 12 at any time despite non pharmacological 
interventions. If the infant scores remain elevated (greater than 8 times two consecutive scores or 
greater than 12 times one) the dose of oral morphine is increased to a maximum dose of (0.08 
mg/kg/dose every 3 hours with feedings). If the infant continues to demonstrate elevated scores 
(greater than 8 times two consecutive scores) on the maximum dose of morphine the infant may 
be started on oral clonidine (1 mcg/kg/dose every 6 hours) provided there are no 
contraindications. The dose of clonidine can be gradually increased to maximum dose of (2 
mcg/kg/dose every 3 hours). If the infant continues to evidence persisting elevated modified-
FNAST scores (greater than 8 times two consecutive scores) on maximum doses of morphine 
and clonidine, the infant may be treated with a loading dose of oral phenobarbital 
(20mg/kg/dose), followed 12 hours later by maintenance phenobarbital at a dose of (5 mg/kg/day 
divided every 12 hours). Phenobarbital may be increased by 0.5 mg/kg/dose (1mg/kg/day) for 
continued elevated scores (greater than 8 times two consecutive scores). Once the infant is 
stabilized with modified-FNAST scores less than six the infant is gradually weaned off 
pharmacological management according to the protocol. Morphine is weaned first, followed by 
clonidine, and then phenobarbital. Infants must be weaned completely off morphine and 
clonidine prior to discharge. However, infants may be discharged home on phenobarbital with 
continued weaning by protocol out patient at the pediatrician office based on scores.  
A repeated measures Mixed Effect Model was used to compare the mean Finnegan scores 
between the different medication groups (clonidine and phenobarbital) (Tabachnick, & Fidell, 
2013). The results revealed that treatment with clonidine vs. no treatment with clonidine was 
significantly correlated with higher total modified-FNAST scores over time. Treatment with 
phenobarbital vs. no treatment with phenobarbital was not significantly associated with higher 
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modified-FNAST scores. Infants who required treatment with clonidine in addition to morphine 
probably were experiencing more severe and persisting generalized autonomic related symptoms 
of acute drug withdrawal and potentially from a combination of both narcotic and nonnarcotic 
drugs. Phenobarbital was not significantly associated with higher modified-FNAST scores 
possibly because the symptoms infants in this group were experiencing were more easily 
controlled with phenobarbital and a greater number of infants were treated with phenobarbital 
when compared to clonidine. Phenobarbital has been shown to be effective for controlling drug 
withdrawal symptoms from narcotics related to irritability, hyper excitability, and seizures 
(Gomella, Cunningham, & Eyal, 2013). It is not effective in controlling gastrointestinal 
symptoms of drug withdrawal related to nonnarcotic agents (Gomella, Cunningham, & Eyal, 
2013). All other controlled variables (including gender, birth weight, gestational age, and 
estimated number of cigarettes smoked per day by the mother) were not significantly associated 
with increased total modified-FNAST scores. 
The traditional score based care model utilized at the study site is consistent with a recent 
national survey of management strategies used in the care of infants with NAS in US NICUs 
(response rate of 47%). According to the survey, the Finnegan or modified-FNAST were the 
most commonly used instruments to measure the severity of withdrawal across United States 
(US) NICUs (65-95.5%) (Mehta, Forbes, & Kuppala, 2013). In addition, the survey revealed that 
95% of NICUs offered some aspect of non-pharmacological interventions, 26% relied primarily 
on non-pharmacological interventions, and 54.1% utilized a combination of pharmacological and 
non-pharmacological interventions (Mehta, Forbes, & Kuppala, 2013). 
This traditional score-based model of care which includes hospitalization in the NICU 
and treatment based primarily on modified-FNAST scores is commonly used among US 
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hospitals (Marcellus, 2018; Wachman, et al., 2018). Concerns related to the complexity of 
scoring the instruments, training and maintaining staff reliability in scoring using an instrument, 
variability of scores related to subjectivity in scoring, and lack of reliability in scoring among 
staff have been reported (D’Apolito, & Finnegan, 2010; Timpson, Killoran, Maranda, Picarillo, 
& Bloch-Salsbury, 2018).The traditional approach to treating infants with NAS was originally 
described by Finnegan, et. al. (1975). Consistent with this model of care, infants with NAS are 
assessed after every feeding every 3-4 hours using a valid and reliable abstinence scoring 
instrument. According to the AAP 2012 guidelines, nonpharmacological interventions are 
implemented first, however, if the modified-FNAST scores remain elevated the infants are 
started on pharmacological treatment according to an established NAS weaning protocol (Hudak 
& Tan, 2012). This traditional model of care for infants with NAS and treatment approach based 
primarily on Finnegan scores has recently been questioned. The traditional model has been 
recently challenged because treatment decisions based primarily on total modified-FNAST 
scores may have the potential to result in overtreatment (including unnecessary or extended 
hospitalization in the NICU and or pharmacological treatment), escalating costs, and 
unnecessarily separating mother-infant dyads which can result in impairment in mother infant 
bonding (Marcellus, 2018; Wachman, et al., 2018). 
In contrast to the traditional score based model, Grossman, et al. (2017) proposed the Eat, 
Sleep, and Console (ESC) functional infant model (as part of a quality improvement initiative) as 
a basis for making treatment decisions for infants with NAS. Family centered care and 
nonpharmacological interventions are implemented first. Nonpharmacological interventions 
include promoting breastfeeding, maternal rooming in, skin-to-skin, and reduction of 
environmental stimuli have empirical evidence to support reductions in modified-FNAST scores, 
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length of stay, and reduction in medication treatment dose and duration in infants with NAS 
(Edwards and Brown, 2016; Green & Goodman, 2003; Hodgson & Abrahams, 2012; Marcellus, 
2007; Newman et al., 2015; Pritham, 2013; Ryan, Dooley, Finn, & Kelly, 2018; Velez & 
Jansson, 2008). Infants with NAS who are unable to perform essential functions characteristic of 
a healthy newborn (eat a minimum of at least 1 ounce per feeding or breastfeed, sleep greater 
than or equal to one hour, and be consoled within 10 minutes from a cry state) after maximizing 
the implementation of nonpharmacological interventions are considered for treatment with as 
needed doses of medication (Grossman, et al., 2018). The ESC instrument was developed to 
assess the functional status of the infant and reduce the potential for over treatment of infant drug 
withdrawal based solely on the total infant withdrawal score. Infants with NAS who are eating, 
sleeping, and easily consoled are considered to be stable. Infants with NAS who are unable to 
maintain their functional status according to the established criteria are provided additional 
support with nonpharmacological treatment. If nonpharmacological treatment alone is no longer 
sufficient in allowing the infant to maintain a reasonable functional status, the infant is treated 
with a dose of 0.05mg/kg of oral morphine and then reassessed (Grossman, et al., 2018). 
Grossman, et al. (2017) conducted a retrospective chart review to compare the treatment 
decisions of 50 infants with NAS who were clinically assessed using the ESC approach. The 
findings suggest that using the ESC criteria resulted in only 6 (12%) of the infants requiring 
treatment with morphine compared to 31 infants (62%) predicted to require treatment using the 
Finnegan Neonatal Abstinence Scoring System (which was statistically significant, p < .001). In 
addition, the overall average length of stay was reduced to 5.9 days compared to an estimated 10 
days longer if the infants were managed using the traditional score based approach, and the 
average length of stay was also reduced in the infants who required treatment with morphine to 
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control withdrawal symptoms from 16.9 to 12.3 days (Grossman, et al., 2018).  There were no 
reported adverse events (such as seizures or failure to thrive) or readmissions during the study 
period (Grossman, et al., 2018).  
The findings from this retrospective chart review revealed that mothers in this sample had 
experienced mental health related problems (including anxiety, depression, panic and bipolar 
disorders) and trauma related events (including domestic violence, rape, baker acted, suicide 
attempt, and incarceration). This is consistent with the literature which suggests that advocacy, 
respectful, non-judgmental, harms reduction, and trauma-informed care models need to be 
integrated in any model of care for this high-risk population of mother-infant dyads to provide a 
safe, therapeutic environment to reduce unnecessary stress and anxiety for women who have 
experienced or are at risk for facing trauma (Marcellus, 2014; Marcellus, 2018). Comprehensive 
care models that ensure collaboration between psych-mental health professionals, addiction 
specialists, obstetricians, neonatologists, nursing, lactation, social work, drug court and child 
protective services are also recommended to prepare the mother to safely care for her infant, and 
link her with essential community resources (access and transportation to access prenatal, safe 
housing, and job skills) in order to promote the long term recovery of the mother and improve 
the neurodevelopmental outcomes for the infant (O'Connor et al., 2013).  
Future studies need to examine the modified-FNAST to determine if further modification 
will be necessary to ensure the validity and reliability of the drug withdrawal severity scores 
generated in critical subpopulations of infants with NAS for whom there are no valid and reliable 
instruments including preterm infants and infants greater than 28 days of life. 
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Limitations 
This was a retrospective study designed to analyze existing hospital data collected from 
January 1, 2010 to May 18, 2018. As a result the study is subject to many possible biases and 
threats to the internal and statistical conclusion validity. Other risk factors or confounding 
variables may have been present that were not measured. The accuracy of the data is only as 
reliable as what was documented in the electronic medical record, which may lead to 
ascertainment bias and/or missed cases. The data were collected over an 8 year time period in 
which maternal drug dependence patterns, and NAS weaning protocols have changed which 
were not accounted for.  
Multiple variables related to maternal demographics (including race, ethnicity, highest 
level of education achieved) could not be reported for most of the women because they were not 
documented in the EMR as part of the NICU medical admission or discharge notes, and the 
mothers were not inpatients of the study hospital. This posed limitations on the description of the 
demographics of the sample of mothers. In addition, although the study team members who 
completed the data extraction from the EMR were trained, monitored, and used standardized 
abstraction forms (based on the a priori coding rules and definitions), they were not blinded to 
the hypotheses being tested which may have introduced bias. The study population included 
infants with NAS from a single study site which may also pose limitations to the generalizability 
of the study findings. 
Implications for Clinical Practice and Future Research 
The traditional model of care for infants with NAS utilizing primarily an abstinence score 
based approach may need to be re-examined in light of the promising clinical outcome results 
(reduction in need for pharmacological treatment and reduced length of hospital stay) reported in 
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recent quality improvement initiatives utilizing functional assessment based approach (ESC 
approach) (Grossman, et al., 2018). Respectful, non-judgmental, harms reduction, and trauma 
based care models need to be considered and empirically tested. Finally, care models that ensure 
collaboration between psych-mental health professionals, addiction specialists, obstetricians, 
neonatologists, lactation specialists (to support breastfeeding), nursing (to provide maternal 
education regarding infant care), social work, child protective services, and community services 
(access to medical and dental care, housing, and job training) are also recommended to break the 
cycle of addiction and promote long term recovery in the mother (O'Connor et al., 2013). 
Combined inpatient and outpatient weaning programs such as the Managing Abstinence in 
Newborns (MAiN) program for carefully selected mother-infant dyads need to be further 
developed and tested (Summey, et al., 2018). These different models of care and assessment 
approaches need to be tested using large scale randomized controlled trials to determine which 
approach or combination are most efficacious, cost effective, support the mother in her recovery, 
treat the infant for NAS, and are shown to improve the long-term neurodevelopmental outcomes 
for this high-risk population of infants. In addition, large scaled randomized controlled trials are 
necessary to determine which opioid derivatives are the most safe and efficacious and are shown 
to have best neurodevelopmental outcomes. Commonly prescribed opioids (including 
methadone, morphine, buprenorphine, alone and in combination with phenobarbital and 
clonidine) need to be tested side by side in multiple arms of randomized controlled trials to 
provide reproducible empirical evidence, potentially leading to the development of standardized 
national medication treatment protocols for this high-risk population of NAS infants. Infants 
with NAS who have been exposed prenatally to opioids and benzodiazepines must be included in 
these studies as this sub-population of high-risk infants has historically been excluded from 
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previous drug studies and represents an increasing number of infants. The modified-FNAST 
needs to undergo additional psychometric testing and potentially modification to ensure the 
validity and reliability of the drug withdrawal severity scores generated in critical subpopulations 
of infants with NAS for whom there are no valid and reliable instruments including preterm 
infants and infants greater than 28 days of life. 
Summary 
The final chapter of this dissertation provided an overview of the important study 
findings. In addition, an exploration of how the study findings from this retrospective chart 
review validated or conflicted with the existing published literature was discussed. The 
limitations of the study were presented and implications for current practice and future research 
were explored.  
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APPENDIX A: 
SYNTHESIS TABLE  
 
Synthesis of the Empirical Referents & Evidence on the Care and Treatment of Infants with NAS  
Screening and Measurement Instruments for Infants at Risk for NAS 
Author, year, 
and location 
Design, sample size, 
purpose, and instruments 
Findings and limitations of the study 
Murphy-
Oikonen, et al., 
2010 
Canada 
Retrospective chart review;  
n = 21 pre implementation of the 
protocol compared to n = 70 in the 
post group 
Purpose: To determine if the use of 
standardized screening protocol 
(combining maternal self-report, with 
mother and infant urine and meconium 
drug testing) could accurately detect 
infants at risk for NAS. 
Instruments: Modified- Finnegan 
Neonatal Abstinence Scale Tool (M-
FNAST) 
Findings: The use of the protocol resulted in 29% 
more infants being identified with NAS. There were 
discrepancies between the maternal self-report and 
the urine and meconium drug screen results. Urine 
drug screen results available within 24-72 hours. 
Meconium drug screen results took longer to get 
back, but more accurately reflected drug use over 
the course of the pregnancy. Therefore the authors 
recommended using all three methods to improve 
screening accuracy. 
Limitations: This study was a retrospective chart 
review therefore the data extracted from the 
documentation in the medical records may not be 
complete. 
Finnegan, et al., 
1975 
United States 
 
Psychometric Testing;  
n = 37 term and near term infants born 
to drug dependent mothers in 
Philadelphia were assessed using the 
instrument. 
Purpose: To assess the validity of the 
inferences of the scores using the 
Finnegan to assess the severity of drug 
withdrawal in infants with NAS. 
Instruments: Finnegan Neonatal 
Abstinence Scoring Tool (FNAST) 
Findings: NAS infants with score ranges up to 7 
were provided with non-pharmacological measures. 
Score values above 8 were determined to be 
pathological, requiring treatment with phenobarbital 
or paregoric. A significant reduction in the 
treatment time was noted for exposed infants 
treated based on the scores generated from the 
instrument compared to infants assessed without an 
instrument (current standard of care). The study 
provided the initial evidence to support face 
validity, and construct validity of the original 
Finnegan instrument to assess the severity of drug 
withdrawal in infants with NAS. 
Limitations: Only 37 infants with NAS were 
included in the sample which poses a limitation to 
the study findings. 
Zimmermann-
Baer, et al., 2010 
 
United States 
 
Psychometric testing;  
n = 102 healthy newborns greater than 
34 weeks gestation whose mothers 
denied illicit drug use during the 
pregnancy.  Meconium and urine 
testing was done on the infants scoring 
Findings: The investigators reported that for the 
first 3 days of life the median M-FNAST scores 
remained stable at 2, but the variability increased 
with 95th percentile rising from 5.5 on day 1 to 7 on 
day 2.  At weeks 5-6 median values were higher 
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high and confirmed that they did not 
have any prenatal drug exposure. 
Purpose: To assess the variability of 
the scores in healthy newborns not 
exposed to illicit drugs. To assess the 
divergent validity of the Finnegan 
Score. 
Instruments: Modified- Finnegan 
Neonatal Abstinence Scale Tool (M-
FNAST) 
during the daytime (50th percentile = 5, and 95th 
percentile = 8).  Healthy infants never exceeded a 
score of 8. The score in healthy newborns increases 
with age related to brain maturation and circadian 
rhythms. Values above 8 are pathological, requiring 
treatment for NAS. Provided evidence for the 
divergent validity of the Finnegan in healthy 
newborn infants. 
Limitations: Different nurses scored the infants at 
the two points in time and the parents also assigned 
infant drug withdrawal scores at weeks 5 or 6. 
Drugs screens were only analyzed on the infants 
with elevated scores. 
D’Apolito & 
Finnegan, 2010 
 
United States 
 
An Inter-Observer Reliability Program 
for Scoring the M-FNAST;  
Purpose: An Inter-Observer 
Reliability Program for Scoring the M-
FNAST. The educational program is   
available on CD. The program 
provides didactic on NAS, 
pharmacological and non-
pharmacological interventions used to 
treat infants with NAS. The program 
also provides an overview of the M-
FNAST. The definitions for scoring 
are reviewed and then the learner is 
guided through a videotaped example 
of an NAS infant being scored using 
the instrument. Then the participant is 
asked to score another NAS infant 
video and achieve 90% reliability with 
the instructor. 
Instruments: 90% reliability scoring 
the M-FNAST to achieve inter-
observer reliability. 
Findings: Provided a program for nurses to achieve 
reliability in scoring the M-FAST. The program is 
targeted for use in NICU’s, Mother-Baby Units, and 
Newborn Nursery to improve the accuracy of the 
nurses scoring the degree of withdrawal in NAS 
infants using the M-FNAST. 
Limitations: The medication dosing protocol 
presented in the program is no longer current, as 
many centers are now using buprenorphine and 
clonidine in addition to morphine and 
phenobarbital.   
Maguire, et al., 
2013 
 
United States 
 
Retrospective chart review;  
33 856 M-FNAST assessments 
obtained from the electronic medical 
records of N = 171 infants admitted to 
an NICU were analyzed. 
Purpose: To complete a factor 
analysis of the M-FNAST instrument 
to provide additional psychometric 
testing to support the validity of the 
inferences of the accuracy of this 
instrument to assess the degree of 
withdrawal in NAS infants 
hospitalized in an NICU. 
Instruments: Principle axis factoring 
(PAF) extraction with Varimax 
rotation was performed on 33 856 M-
FNAST assessments obtained from the 
electronic medical records of 171 
Findings: Provided further evidence for the 
construct validity of the M-FNAST scores to assess 
the severity of drug withdrawal of NAS infants 0-28 
days of life. The finding also suggested that the 2-
factor solution explained 23.74% of the total 
variance. Mild/early (crying, duration of sleep, 
increased muscle tone), and moderate/advanced 
signs (tremors, respiratory rate, sweating and 
excessive sucking). The 2-factor solution short form 
FNAST was significantly correlated with the total 
score on the M-FNAST.   
Limitations: The short form has not been tested 
clinically. May not accurately assess the severity of 
acute drug withdrawal in NAS infants with rapidly 
escalating symptoms due to the limited number of 
items. 
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infants admitted to an NICU were 
analyzed. 
 
 
Grossman, et al., 
2018 
 
United States 
 
Retrospective chart review;   
Purpose: Compared treatment 
decisions of n = 50 consecutive opioid 
exposed infants assessed using the Eat, 
Sleep, Console (ESC) approach vs. 
modified FNAST to determine how 
many infants met the criteria and were 
treated with morphine. 
 
 
 
Findings: Use of the ESC method resulted in only 6 
infants (12%) requiring treatment with morphine (as 
needed) compared to 31 (62%) who would have 
met the treatment criteria if the modified-FNAST 
would have been used (prior clinical practice) The 
infants assessed using the ESC criteria were 
hospitalized less days and there were no 
readmissions or adverse events reported. 
Limitations: This study was a retrospective chart 
review therefore the data extracted from the 
documentation in the medical records may not be 
complete. 
Pharmacological Treatment of NAS 
Author, year, 
and location 
Design, sample size, 
purpose, and instruments 
Findings and limitations of the study 
Osborn, et al., 
2010a 
 
Australia 
 
Meta-Analysis;  
n = 9 studies (randomized and quasi-
randomized trials). N = 645 infants 
met the inclusion criteria. Included 
trials with opiates vs placebo or no 
treatment, comparisons of opioid 
drugs used to treat this population, 
opioids vs sedatives (clonidine, a 
benzodiazepine, barbiturates, or 
neuroleptic agents, and opioids vs 
non-pharmacological interventions. 
Purpose: The purpose of the study 
was to determine the level and quality 
of the evidence (from random and 
quasi-random control trials) that an 
opiate is more effective than a sedative 
or non-pharmacologic treatment of 
clinical significant NAS due to opioid 
withdrawal. 
Instruments: N/A 
Findings: Use of opioids (illicit or prescribed as 
part of a drug treatment program) in pregnant 
women may result in NAS. An opioid should be 
used as initial treatment for withdrawal symptoms 
in infants with NAS exposed to opioids in utero. 
This review is consistent with the AAP (1998) that 
NAS should be treated with the same class of drug 
of exposure in utero. 
Limitations: The results are limited by the relative 
quality and variability of the methods used in the 
studies included. 
 
Osborn, et al., 
2010b 
 
Australia 
 
Meta-Analysis;   
n = 7 studies, n = 385 NAS infants 
Purpose: To assess the safety and 
efficacy of using a sedative compared 
to a non-opioid control for NAS 
secondary to withdrawal from opiates, 
and determine which sedative is the 
safest and most effective. The meta- 
analysis included seven trials enrolling 
infants diagnosed with NAS who were 
born to opioid dependent mothers with 
> 80% follow-up and using quasi-
Findings: The use of opioids by pregnant women 
may result in withdrawal symptoms in their 
newborn infants. Infants treated for NAS are at risk 
for alterations in maternal-infant bonding, 
difficulties with feeding and sleeping, weight loss, 
and seizures. Individual studies have reported that 
phenobarbital compared to supportive care alone 
reduces the time the infant needs supportive care, 
and is better compared to diazepam. Phenobarbital 
is preferred when a sedative is needed to control 
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random or random allocation to 
sedation or control group.  Control 
could include other sedatives or non-
pharmacological treatment. 
Instruments: N/A 
persisting CNS symptoms in newborns with opioid 
withdrawal due to in utero exposure to opioids. 
Limitations: The results are limited by the relative 
quality and variability of the methods used in the 
studies included. 
Brown, et al., 
2015 
 
United States 
Single site, prospective, double-
masked, randomized trial. 
n = 15 were randomized into the 
methadone group and n = 16 were 
randomized into the morphine group. 
Purpose: The purpose of the study 
was to test the hypothesis that the 
length of treatment for NAS in the 
methadone group would be shorter 
than the length of treatment required 
for the morphine group. 
Instruments: Finnegan scores 
Findings: 
The results revealed that length of opioid treatment 
was shorter for the methadone group (median = 14 
days) as compared to the morphine group (median = 
21days) which was statistically significant (p = 
0.008). 
Limitations: The sample size was small and limited 
to one unit. 
Davis, et al., 
2018 
 
United States 
Single site, randomized, double-blind, 
intention-to-treat trial. 
n = 59 were randomized into the 
methadone group and n = 58 were 
randomized into the morphine group. 
Purpose: The purpose of the study 
was to test the hypothesis that the 
length of hospital stay and length of 
treatment in the methadone group 
would be shorter than the length of 
hospital stay and length of treatment 
required for the morphine group. 
Findings: 
The results revealed that the length of hospital stay 
was 14% shorter (by 2.7 days) and a 16% reduction 
in the length of treatment (by 2.3 days) for the 
methadone group as compared to the morphine 
group which were both statistically significant p = 
.01, and p = .02 respectively. 
Limitations: The sample size was small and limited 
to one unit. 
Kraft et al., 
2008 
 
United States 
 
Single site, randomized, phase I, open-
label, placebo controlled trial 
comparing sublingual buprenorphine 
to oral morphine. Term infants n = 26 
requiring pharmacological treatment 
for NAS were randomized n = 13 to 
buprenorphine and n = 13 to neonatal 
opium (NOS) group. 
Purpose: To determine the safety and 
efficacy of buprenorphine compared to 
NOS for the treatment of infants with 
NAS born to mothers with opioid 
dependence. 
Instruments: Pharmacological 
treatment for NAS, and length of 
hospital stay. Withdrawal scores 
assessed using the MOTHER NAS 
score.  
Findings: Buprenorphine administered (at a dose of 
13 mcg to 39 mcg/kg/day in three divided doses 
every 8 hours) sublingually is feasible and safe for 
the treatment of NAS. The investigators reported 
that 98% of the plasma concentrations were 
reported to be undetectable to 0.6 ng/ml, which is 
less than what is required to treat adults with 
abstinence syndrome. The mean length of treatment 
for infants treated with buprenorphine was 22 days 
compared to 32 days in the infants treated with 
NOS (standard of care). The mean length of stay for 
the buprenorphine group was 27 days compared to 
38 days in the NOS group. 
Limitations: The small sample size did not provide 
adequate power to support the study findings 
reported. Infants with exposure to both opioids and 
benzodiazepines were excluded from the study. 
Kraft et al.,  
2011 
 
United States 
Single site, randomized, phase I, open-
label, placebo controlled trial 
comparing sublingual buprenorphine 
to oral morphine. Term infants n = 24 
Findings: Buprenorphine administered (at a dose of 
15.2 mcg/kg/day to 60 mcg/kg/day in three divided 
doses every 8 hours) sublingually is feasible and 
safe for the treatment of NAS. Infants treated with 
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 requiring pharmacological treatment 
for NAS were randomized n = 12 to 
buprenorphine and n = 12 to neonatal 
opium (NOS) group. 
Purpose: To determine the safety and 
efficacy of buprenorphine compared to 
oral morphine in the treatment of 
infants with NAS born to mothers with 
opioid dependence. Dose optimized 
treatment plan: increasing the initial 
dose, increasing the rate of dose 
escalation to control symptoms, and 
increasing the maximum total dose. 
Instruments: Pharmacological 
treatment for NAS, and length of 
hospital stay. Withdrawal scores were 
assessed using the MOTHER NAS 
score. 
buprenorphine required a 23-day length of 
treatment compared to 38-days in the morphine 
treated group (p= 0.01) which represented a 40% 
reduction in the length of treatment. Length of 
hospital stay was reduced from 42-days in the 
buprenorphine group to 32-days (p = .05), 
representing a 24% reduction in length of hospital 
stay. Three infants in the buprenorphine group 
required phenobarbital, compared to one in the 
morphine group. 
Limitations: The small sample size did not provide 
adequate power to support the study findings 
reported. Infants with exposure to both opioids and 
benzodiazepines were excluded from the study. 
Kraft & van den 
Anker, 2012 
 
United States 
 
Secondary data analysis, combined the 
data from two randomized, phase I, 
open-label, placebo controlled trial 
comparing sublingual buprenorphine 
to oral morphine. The sample 
consisted of n = 50 term infants 
requiring pharmacological treatment 
for NAS. 
Purposes: To determine the optimal 
dose of sublingual buprenorphine 
necessary to treat NAS in infants 
exposed to opioids in utero. The dose 
optimized treatment plan consisted of: 
increasing the initial dose, increasing 
the rate of dose escalation to control 
symptoms, and increasing the 
maximum total dose. 
Instruments: Pharmacological 
treatment for NAS, and length of 
hospital stay. Withdrawal scores were 
assessed using the MOTHER NAS 
score. 
Findings: Infants treated with buprenorphine 
required a mean 23-day length of treatment 
compared to 34-days in the morphine treated group 
(p= 0.001) representing a 36% reduction in the 
length of treatment. Length of hospital stay was 
reduced in the buprenorphine group by 29% (p = 
.006). Six of the 25 infants in the buprenorphine 
group required phenobarbital, compared to two in 
the morphine group. 
Limitations: The small sample size did not provide 
adequate power to support the study findings 
reported. Infants with exposure to both opioids and 
benzodiazepines were excluded from the study. 
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Agthe et al., 
2009 
 
United States 
 
 
 
 
 
Randomized control trial of clonidine 
compared to placebo as an adjunct to 
morphine treatment for patients with 
NAS. The sample consisted of n = 40 
infants with NAS with in utero 
exposure to opioids. 
Purpose: The purpose of this study 
was to determine the effectiveness of 
clonidine compared to placebo 
combined with morphine as an adjunct 
medication on total morphine dose and 
length of hospital stay in infants with 
NAS with in utero exposure to 
opioids. 
Instruments: Pharmacological 
treatment for NAS (total dose of 
morphine), and length of hospital stay. 
Findings: Clonidine was tolerated well without 
reported significant hypotension or bradycardia in 
the infants. The morphine/clonidine group had 
statistically significant shorter lengths of hospital 
stay of 11 days (95% CI: 8-15) compared to 15 days 
in the morphine/placebo group (CI: 13-17). The 
total morphine dose was 7.7 mg with combined 
morphine/clonidine compared to 19.2 mg 
morphine/placebo, (p=.03). An incidence of SVT 
was reported in one infant 3 days post 
discontinuation of the clonidine. Three infants in 
the clonidine group died with autopsy verified 
findings of (myocarditis, SIDS, and homicide 
(methadone overdose).  Each of the infant deaths 
occurred at least 22 days after discontinuation of the 
study drug and was assessed to be unrelated. The 
authors concluded that rapid clearance of clonidine 
by neonates in the first month of life may be 
causally associated with the infant adverse events 
reported with the drug in this study. Therefore, they 
cautioned that dosage and weaning needs further 
study to better understand the pharmokinetics and 
long term safety of the drug in this high-risk 
population of infants. 
Limitations: Small sample size was a limitation in 
this study.  
Surran, B., et al., 
2013 
 
United States 
 
Prospective, non-blinded, block 
randomized trial at a single level III 
NICU; The sample consisted of n = 82 
infants > 35 weeks requiring treatment 
(methadone or morphine for in utero 
exposure to opioid) were eligible, of 
which n = 68 were randomized into 
each group. 
Purpose: The purpose of this study 
was to compare the efficacy of 
clonidine vs phenobarbital in reducing 
morphine sulfate treatment days for 
NAS. 
Instruments: Pharmacological 
treatment for NAS (total dose of 
morphine), and length of hospital stay. 
Findings: Adjusting for covariates phenobarbital as 
compared with clonidine was shown to have shorter 
morphine treatment days, with no difference in 
average morphine dose. Post- discharge 
phenobarbital was continued for an average of 3.8 
months. There were no differences in both groups 
related to total morphine dose suggesting that both 
drugs were equally effective in controlling NAS 
symptoms. Phenobarbital as adjunct therapy had 
clinically nonsignificant shorter inpatient but 
significant overall longer therapy time as compared 
with clonidine. The infants on clonidine had the 
medication discontinued prior to discharge. These 
results are significant given the concerns about the 
long-term outcomes from prolonged phenobarbital 
exposure on the developing brain. This study 
provides further support for the use of clonidine as 
an alternative to phenobarbital. 
Limitations: Included the inability to blind the two 
groups for the study medications due to different 
dosing units, intervals, and clinical monitor 
required. 
Burke, & 
Beckwith, 2017 
 
Retrospective chart review; 36 Infants 
with NAS (n = 17 treated with 
Findings: Infants treated with morphine were noted 
to have higher mean scores on the Bayley-III on the 
Cognitive Composite (91.3 compared to 83 with a p 
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United States methadone, and n = 19 treated with 
morphine). 
Purpose: The purpose of this study 
was to compare the 
neurodevelopmental outcome of 
infants treated for NAS with 
methadone compared to morphine. 
Instruments: Bayley Scales of Infant 
and Toddler Development- Third 
Edition (Bayley-III) at 3 to 7 days 
prior to discharge. 
= 0.03410), and total Motor Composite (96.3 
compared to 89.6 with a p = 0.0149) when 
compared to infants who were treated with 
morphine monotherapy. Mean age at the time of 
neurodevelopmental testing was 50 days in the 
morphine group and 46 days in the methadone 
group. 
Limitations: This study was a retrospective chart 
review therefore the data extracted from the 
documentation in the medical records may not be 
complete. The small sample size may also be a 
limitation in this study. The infants were not 
followed over time. 
Gullickson, et 
al., 2018 
 
Canada 
Retrospective chart review; 174 
Infants with NAS (n = 22 treated with 
morphine alone, and n = 100 treated 
with morphine combined with 
clonidine). 
Purpose: The purpose of this study 
was to determine whether treating 
infants diagnosed with NAS with 
clonidine combined with morphine 
would result in a reduction in the 
length of treatment compared with 
morphine alone.  
Instruments: Pharmacological 
treatment for NAS (maximum dose of 
morphine), and length of treatment. 
Findings: Infants treated with a combination of 
morphine and clonidine were noted to have 
statistically significant longer lengths of treatment 
(p = 0.004), and higher peak morphine doses (p = 
0.045) when compared to infants who were treated 
with morphine monotherapy. 
Limitations: This study was a retrospective chart 
review therefore the data extracted from the 
documentation in the medical records may not be 
complete. The small sample size in the morphine 
only group may also be a limitation in this study. 
Hall, et al.,   
2015 
 
United States 
 
Retrospective chart review; Infants 
with NAS (> 35 weeks requiring 
treatment (methadone or morphine for 
in utero opioid exposure) who were 
treated at the 3 sites with existing 
weaning protocols (controls) n = 813 
infants (454 before adoption and 359 
after). Infants with NAS treated at the 
3 sites without prior weaning protocols 
(treatment) n = 168 infants (75 before, 
and 93 after). 
Purpose: The purpose of this study 
was to evaluate the generalizability of 
stringent protocol-driven 
pharmacological weaning to reduce 
the total duration of opioid treatment 
and length of inpatient hospital stay in 
infants treated for NAS.  
Instruments: Pharmacological 
treatment for NAS (duration of 
opioid), and length of hospital stay. 
Findings: After adoption of the multicenter 
weaning protocol for infants with NAS, the 3 
groups previously without a strict protocol noted a 
statistically significant reduced duration of opioid 
treatment length (23 vs 34 days, p < .001) and  a 
reduction in hospital length of stay ( 23.7 vs 31.6 
days, p < .001). Outcomes were sustained in the 3 
hospital groups that previously were following the 
strict weaning protocol (duration of treatment = 17 
days, and length of stay = 23.3 days). 
Implementation of a standard weaning protocol for 
infants treated for NAS reduced duration of opioid 
exposure and length of hospital stay in 6 children’s 
hospitals in Ohio. 
Limitations: Study limited to 6 centers from one 
Ohio health system which reduces the 
generalizability of the findings. 
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Non-Pharmacological Treatment of NAS 
Author, year, 
and location 
Design, sample size, 
purpose, and instruments 
Findings and limitations of the study 
Frazer, et al., 
2007 
 
Australia 
 
Interpretative methods descriptive 
study;  
n = 8 nurses from four Special Care 
Nursery Units 
Purpose: The purpose of this study 
was to explore neonatal nurses’ 
experiences of providing care to drug-
exposed newborns and their parents 
over the duration of hospitalization for 
NAS. 
Instruments: Group Interviews 
Findings: Supported the use of cuddlers to provide 
comfort care to the infants and lessen the workload 
on the nurses. Five themes emerged from the data: 
the relationship with the baby; response to the 
family; tensions within the care environment; 
nurse’s needs; and making a difference. The results 
of this study indicated that management of these 
babies and their parents is compromised by a range 
of attitudinal and organizational factors. The 
investigators concluded that there is a need to 
address these barriers in order to optimize patient 
care delivery, and improve neonatal nurse’s impact 
on promoting parent infant bonding. 
Limitations: Only 8 nurses were included in the 
sample which poses a limitation to the study 
findings. 
Green, & 
Goodman, 2003 
 
United States 
 
 
Case series, descriptive; included 
studies related to the care of infants 
with NAS. 
Purpose: Description of the state of 
the art care for in utero drug-exposed 
infants. 
Instruments: Descriptive review of 
empirical evidence on non-
pharmacological interventions to 
support infants with NAS. 
Findings: The study provided limited empirical 
evidence for the use of multiple non-
pharmacological interventions in the care of infants 
with NAS. Quiet environment, non-nutritive 
sucking, vestibular stimulation (gentle vertical 
rocking), minimal handling was used to provide 
non-pharmacological support for infants with NAS, 
and was reported to be beneficial in this descriptive 
case series. 
Limitations: Descriptive case series study, 
therefore, the generalizability of the findings are 
limited. 
Marcellus, 2007 
 
United States 
 
Case series, descriptive; included 
studies related to the care of infants 
with NAS. 
Purpose: Description of the state of 
the art care for in utero drug-exposed 
infants. 
Instruments: Descriptive review of 
empirical evidence on non-
pharmacological interventions to 
support infants with NAS. 
Findings: The study provided limited empirical 
evidence for the use of multiple non-
pharmacological interventions in the care of infants 
with NAS. Holding, swaddling, and minimal 
stimulation was used to provide non-
pharmacological support for infants with NAS, and 
was reported to be beneficial in this descriptive case 
series. 
Limitations: Descriptive case series study therefore 
the generalizability of the findings are limited. 
Valez, & 
Jansson, 2008 
 
United States 
 
 
Case series, descriptive; included 
studies related to the care of infants 
with NAS. 
Purpose: Description of the state of 
the art care for in utero drug-exposed 
infants. 
Instruments: Descriptive review of 
empirical evidence on non-
Findings: The study provided limited empirical 
evidence for the use of multiple non-
pharmacological interventions in the care of infants 
with NAS. Pacifier, quiet or low stimulation 
environment, positioning supine, slow vertical 
rocking, gentle pressure to posterior head was used 
to provide non-pharmacological support for infants 
with NAS, and was reported to be beneficial in this 
descriptive case series. 
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pharmacological interventions to 
support infants with NAS. 
Limitations: Descriptive case series study therefore 
the generalizability of the findings are limited. 
White-Trout et 
al., 2002 
 
United States 
 
 
Prospective randomized clinical trial;  
n = 45 drug exposed infants were 
enrolled in the treatment group, and n 
= 72 non-exposed infants in the 
control group. 
Purpose: The purpose of this study 
was to compare the responses of non-
exposed and drug-exposed newborns 
to an auditory, tactile, visual, and 
vestibular (ATVV) intervention. 
Instruments: Infant behavior state 
(IBS), and pulse rate (PR) were 
measured. 
Findings: The investigators reported that the non-
exposed and drug-exposed control groups (p = 
0.021) differed on the distribution of IBS. However, 
they found no differences between the two 
experimental groups. Non-exposed and drug-
exposed infants in the treatment group experienced 
greater alertness and decreased quiet sleep when 
compared to controls (p < 0.05). PR and IBS were 
significantly correlated for all but the drug- exposed 
control group (non-exposed control, r = 0.938, p = 
0.006; non-exposed experimental, r = 0.979, p = 
0.001; drug- exposed experimental, r = 0.955, p = 
0.003). Within the combined (experimental and 
control) drug-specific groups, only polydrug- 
exposed infants demonstrated such a correlation (r 
= 0.584, p = 0.046). A significant correlation was 
also identified within the cocaine-exposed group for 
the experimental only (r = 0.992, p < 0.001). The 
investigators therefore concluded that the ATVV 
promoted normal physiologic and behavioral 
function. 
Limitations: The sample size was small and the 
infants were observed over a 12 hour time frame in 
the early postnatal when many behavioral and 
physiological adjustments are normally taking 
place. Lastly, the mothers who agreed to participate 
in the study may be different (with respect to 
critical characteristics) from the mothers who 
decided not to participate. 
Oro, & Dix, 
1988 
 
United States 
 
 
 
Quasi experimental study;  
n = 30 narcotic exposed infants with 
confirmed urine toxicology studies 
were enrolled in the study.  All were 
full term except for two preterm (34-
35 weeks gestational age) infants who 
served as matched pairs. The infants 
were matched (type of drug exposure, 
methadone dose when appropriate, 
ethnicity, gestational age, birth weight, 
medication, and initial M-FNAST 
score) n = 15 to non-oscillating 
waterbed or n = 15 traditional 
bassinette. 
Purpose: The purpose of this study 
was to assess the efficacy of non-
oscillating waterbeds compared to 
traditional bassinette for supportive 
care of NAS infants, M-FNAST 
scores, amount of pharmacological 
Findings: The investigators reported that the 
matching process was successful in assuring the 
comparability of treatment and control groups. The 
infants in the waterbed group had a less severe 
course of NAS, their CNS sub-scores were lower, 
they required less pharmacological treatment 
(required less phenobarbital dosage, and a greater 
number of infants weaned of pharmacological 
treatment prior to discharge), and had improved 
weight gain compared to control group. 
Limitations: Only 30 narcotic exposed infants with 
NAS were included in the sample which poses a 
limitation to the study findings. 
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treatment required, and pattern of 
weight gain. 
Instruments: M-FNAST scores, 
amount of pharmacological treatment 
required, and pattern of weight gain. 
D’Apolito, 1999 
 
United States 
 
Repeated measure experimental 
design;  
n = 14 infants exposed to methadone 
and other illicit drugs in utero. 
Purpose: The purpose of this study 
was to determine if the use of a 
mechanical rocking bed with maternal 
intrauterine sounds would decrease 
symptoms of withdrawal and promote 
neurobehavioral adaptation in infants 
with NAS exposed to methadone and 
other illicit drugs in utero. 
Instruments: Neonatal Abstinence 
Scoring System – was used to measure 
the degree of drug withdrawal. 
Braselton Neonatal Behavioral 
Assessment Scale (BNBAS) 
Findings: The infants in the treatment group 
(mechanical rocking bed) had higher NAS 
withdrawal scores (p = .05), and increased sleep 
disturbances (p = .05). The results suggest that 
rocking beds may be too stimulating for infants 
with NAS in the acute phase of withdrawal from 
methadone or other illicit drugs. Therefore, the 
investigator concluded that mechanical rocking 
beds should not be used in this fragile population of 
infants until further studies have been conducted. 
Limitations: Only 14 infants with NAS were 
included in the sample which poses a limitation to 
the study findings. 
Wolfgang, et al., 
2015 
 
Austria 
 
Prospective, randomized controlled, 
blinded, single-center trial; n = 14 
were randomized to the treatment 
group (laser acupuncture combined the 
pharmacological therapy), and n = 14 
were randomized to the control group 
(pharmacological therapy alone). 
Purpose: The purpose of this study 
was to determine if infants randomly 
allocated to laser acupuncture 
(combined with pharmacological 
therapy of morphine and 
phenobarbital) or control group 
(pharmacological therapy alone) 
would reduce the duration of treatment 
required in NAS infants. Infants born 
to mothers with polydrug abuse were 
excluded. 
Instruments: Measured the duration of 
pharmacological (morphine) therapy. 
Highest Finnegan score, time to 
highest Finnegan score, and length of 
hospital stay. 
Findings: The infants in the treatment group 
(combination of laser acupuncture and 
pharmacological management) had shorter duration 
of oral morphine treatment when compared to 
infants in the control group (pharmacological 
management only). The acupuncture group required 
oral morphine for 28 days vs. 39 days in the control 
group. 
Limitations: Only 28 infants with NAS were 
included in the sample which poses a limitation to 
the study findings. 
 
Jansson, et al., 
2004 
 
United States 
 
 
 
 
Systematic review of the literature; n = 
8 studies were included 
Purpose: Comprehensive review of 
the literature on methadone 
maintenance and lactation to assess the 
amount of methadone in breastmilk to 
determine if it is safe to feed infants 
with NAS. 
Findings: The American Academy of Pediatrics 
(AAP) 2012 guidelines support breastfeeding in 
methadone treated mothers, provided they are in a 
drug treatment program, HIV negative, and not 
using other illicit drugs (heroin, phencyclidine 
(PCP), cocaine, and amphetamines). There are 
additional contraindications for mothers of NAS 
infants with psych mental health problems requiring 
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Instruments: Included studies on 
methadone maintenance and lactation 
to assess the amount of methadone in 
breastmilk to determine if it is safe to 
feed infants with NAS. 
pharmacological treatment (lithium, fluoxetine, and 
Haldol). Hepatitis C is not a contraindication to 
breastfeeding; however, the CDC recommends 
mothers who are positive for hepatitis C consider 
abstaining from breastfeeding if their nipples are 
cracked or bleeding. Based on their review of the 
literature the investigators concluded that the 
amount of methadone in the breastmilk is low and 
that breastfeeding is safe in this population. In 
addition, the investigators suggested that to be 
successful with breastfeeding mothers of NAS 
infants need lactation consultants with additional 
training on NAS. 
Limitations: The 8 studies included had small 
sample sizes, and therefore the short and term 
developmental effects of methadone in breastmilk 
are inconclusive in this population. 
McQueen, et al., 
2011 
 
Canada 
Retrospective chart review;  
n = 28 infants were exposed to 
methadone in utero and developed 
NAS.  n = 8 mostly breastfed (75% or 
more feedings), n = 11 combination of 
breastmilk and formula, n = 9 mostly 
formula fed.  
Purpose: The purpose of the study 
was to determine whether NAS scores 
as measured by the M-FNAST would 
differ based on whether the infant was 
the infant was feed primarily 
breastmilk, a combination of 
breastmilk and formula, or formula 
only 
Instruments: Measured the effect of 
the type of feeding on the  number of 
M-FNAST scores, and mean M-
FNAST scores of the infants 
Findings: There were statistically significant 
differences between the groups in relationship to 
the number of M-FNAST scores obtained on the 
infants. The infants in the mostly breast fed group 
had the lowest, and the lowest mean scores 
compared to the combination breastmilk and 
formula, and formula only groups. The investigators 
therefore concluded that provided there are no 
contraindications (HIV and/or illicit drug use), 
mothers of NAS infants in methadone treatment 
programs should be encouraged to breastfeed. The 
investigators also recommended education on 
benefits of breastfeeding and practical advice on 
how to successfully breastfeed NAS infants (early 
initiation of breast feeding, skin-to-skin, rooming 
in). 
Limitations: This study is a retrospective chart 
review therefore the data extracted from the 
documentation in the medical records may not be 
complete. In addition, the mothers self-selected 
their feeding group, which limits the 
generalizability of the study findings. 
Pritham, et al., 
2012 
 
United States 
Retrospective chart review; 
n = 136 mothers of NAS infants on 
methadone maintenance, and n = 16 
mothers of infants on buprenorphine 
maintenance. 
Purpose: The purpose of this study 
was to examine opioid maintenance 
therapy in pregnancy and its effects on 
neonatal outcomes, and length of stay. 
Instruments: Measured the length of 
hospital stay. 
 
Findings: Exposure to methadone and 
benzodiazepines was associated with increased 
length of stay of 8.6 days for infants with NAS. 
Length of stay was decreased in breastfed infants 
compared to partial breastfed and only formula fed 
infants. The number of days spent in the hospital for 
treatment of NAS was shorter 14 days in the 
buprenorphine group compared to 21 days in the 
methadone group. 
Limitations: This study is a retrospective chart 
review therefore the data extracted from the 
documentation in the medical records may not be 
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complete. In addition, there are many unmeasured 
confounders (maternal length of time in drug 
treatment program and the number of relapses). The 
methadone and buprenorphine group sizes were 
non-equivalent. 
O’Connor, et al., 
2013 
 
United States 
 
 
Retrospective chart review; 
 n = 88 NAS mother infant dyads were 
identified and of these, n = 65 or 76% 
chose to breastfed. 
Purpose: The purpose of this study 
was to examine the rates of 
breastfeeding in opioid dependent 
mothers of NAS infants treated with 
buprenorphine, and determine how 
many continued to breastfeed at 6-8 
weeks post initiation. The study also 
sought to describe the relationship 
between breastfeeding and the 
duration and severity of NAS in this 
sample. 
Instruments: Measured the need for 
pharmacological treatment, and M-
FNAST scores 
 
Findings: The investigators reported that 76% of 
the opioid dependent mothers in the integrated 
medical and behavioral health program treated with 
buprenorphine chose to breastfeed their infants, and 
66% were still breastfeeding at 6-8 weeks 
postpartum. The results suggested that 
breastfeeding may reduce the symptomatology in 
infants with NAS. The breastfeed infants were less 
likely to require pharmacological treatment (15 of 
65 or 23.1% vs 6 of 20 or 30% in the non-
breastfeeding group, and had lower peak NAS 
scores as measured by the Finnegan Scoring System 
(8.83 vs 9.65) compared to infants who were not 
breastfed. 
Limitations: Retrospective chart review therefore 
results cannot be used to establish cause and effect. 
It is not possible to determine the effects of other 
modifying variables such as skin-to-skin care, 
swaddling, and increased maternal contact due to 
the study design. The reasons mothers initiated 
breast feeding or discontinued breastfeeding was 
not available on the mothers in the historical 
controls. 
Wachman, et al., 
2010 
 
United States 
 
Retrospective chart review;  
n = 276 mother infant dyads were born 
July 2003-January 2009 with a 
diagnosis of NAS were assessed for 
inclusion. The mothers were eligible 
to breastfeed if their urine drug screen 
was negative on admission for illicit 
drugs; the mother had no reported 
illicit drug use during the last 
trimester, and was HIV negative. 
Purpose: The purpose of this study 
was to determine breastfeeding rates 
among opioid dependent pregnant 
women delivering at a Baby-Friendly 
Hospital. 
Instruments: Measured the number of 
eligible opioid dependent mother who 
initiated breastfeeding, and the total 
number of days they actually breastfed 
their infants. 
Findings: The investigators reported that of the 276 
dyads, 68% of the mothers met the eligibility 
criteria to breastfeed. Of the 68% of mothers who 
were eligible to breastfeed, 24 % actually breastfed 
their infants to some extent. 60% of the mothers 
who initiated breastfeeding stopped after 5.88 days. 
Limitations: Retrospective chart review therefore 
the data extracted from the documentation in the 
medical records may not be complete. 
Hodgson, & 
Abrahams, 2012 
 
Canada 
Retrospective chart review; n = 295 
mother infant dyads were born 
October 1, 2003-December 31, 2009 
with a diagnosis of NAS who received 
Findings: The study suggested that rooming-in 
could play a useful role in mitigating the 
relationship between maternal methadone dose and 
the need to treat the newborn for opiate withdrawal. 
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care in the rooming in program were 
enrolled. 
Purpose:  The purpose of this study 
was to explore the effect of a rooming-
in program protocol on the need for 
pharmacological treatment of opioid 
exposed newborns. 
Instruments: Collected data on the 
type of drug used by the mother, 
maternal methadone dose at delivery, 
morphine treatment if required on the 
newborn, and perinatal outcomes. 
Rooming-in appears to be a safe alternative to the 
current standard of care which frequently results in 
the separation of mother and newborn in substance-
dependent populations. 
Limitations: Retrospective chart review therefore 
the data extracted from the documentation in the 
medical records may not be complete. 
Brackets, et al.,  
2012 
 
United States 
 
 
Retrospective chart review from 
January 2007 and January 2009; n = 
121 infants born to opiate dependent 
mothers and treated for NAS. Of the 
121 infants, n = 75 received traditional 
pharmacological treatment and 
weaning entirely in the NICU. A sub 
set of carefully selected infants, N = 
46 were initially treated with 
methadone as inpatients and then 
completed their weaning process 
outpatient. 
Purpose: The purpose of this study 
was to compare the safety and efficacy 
of a traditional inpatient only approach 
to a combined inpatient and outpatient 
weaning strategy for infants with 
NAS. 
Instruments: Collected data on the 
type of drug used by the mother, 
duration of methadone treatment, 
breastfeeding rates, readmission and 
child protective services/social 
services referral rates. 
Findings: The investigators reported that in 
carefully selected infants, combined 
inpatient/outpatient weaning compared to 
traditional inpatient only was associated with 
reduced hospital length of stay, treatment duration, 
and increased rates of breastfeeding. Breast feeding 
rates improved: (24% in the combined group vs. 8% 
in the traditional group, p value < .05). Length of 
hospital stay was reduced ranging from 25 + 15 
days for the traditional group, and 13 + 5 days for 
the combined group. Duration of methadone 
treatment was longer 37 + 20 days vs 21 + 14 day, p 
= <0.001). The cumulative dose was similar (3.6 + 
3 vs 3.1 + 5 mg kg/day, p = < 0.42). Concerns 
regarding infant neglect or abuse, and readmission 
rates were similar between the two groups (5% 
traditional, 7% combined). Average cost for infant 
in the combined group was $13 729, compared to 
$27 546 in the traditional group. The investigators 
reported an estimated cost reduction of $635 000 in 
a 2 year period. 
Limitations: Retrospective chart review therefore 
the data extracted from the documentation in the 
medical records may not be complete. 
Smirk, et al., 
2014 
 
Australia 
 
Retrospective chart review; 
n = 38 > 35 weeks gestational age 
infants with NAS who were admitted 
to the NICU and treated for opioid 
dependence (methadone or 
buprenorphine) were selected to be 
transitioned to home based therapy. n 
= 80 were treated as traditional 
inpatients and their outcomes were 
compared. 
Purpose: The purpose of this study 
was to explore the effect of a transition 
program from inpatient to an 
outpatient setting for the treatment of 
opioid exposed newborns. 
Findings: In selected infants, home-based 
detoxification is associated with reduced hospital 
stays and increased rates of breastfeeding, without 
prolonging therapy. Safety of the infants is critical 
which precludes many from entering such a 
program. The investigators reported that the infants 
in the home based detoxification group had shorter 
hospital stays (mean 19 days vs. 41 days). The 
infants in the detoxification group were more likely 
to be breastfeeding on discharge from hospital care 
(45% vs. 22%). 
Limitations: Retrospective chart review therefore 
the data extracted from the documentation in the 
medical records may not be complete. 
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Instruments: Collected data on the 
type of drug used by the mother, infant 
length of stay, cumulative infant 
morphine doses, duration of morphine 
treatment, breastfeeding rates, and 
safety (need for protective services, 
and foster care placement, serious 
adverse events (missed medication 
doses, missed appointments, 
readmissions). 
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